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Abstract 
CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy) represents the most prevalent hereditary form of cerebral small 
vessel disease (SVD) resulting in early-onset stroke and vascular dementia. It is caused by 
stereotyped missense mutations in the transmembrane receptor Notch3, which alter the 
number of cysteine residues in the extracellular domain (ECD). This leads to the abnormal 
multimerization and extracellular deposition of mutant Notch3-ECD at the plasma 
membrane of smooth muscle cells in small blood vessels. Notch3-ECD-containing 
aggregates are the earliest manifestation of the disease and excess Notch3-ECD is believed 
to recruit functionally important extracellular matrix proteins resulting in brain vessel 
dysfunction. 
Biochemical and histological approaches on post-mortem brain tissue from CADASIL 
patients and control subjects as well as in vitro assays were used to study the consequences 
of Notch3-ECD deposition on the ECM components thrombospondin-2, fibrillin-1 and 
fibronectin and members of the latent transforming growth factor-β (TGF-β) binding 
protein (LTBP) family. It is demonstrated that the structural matrix components fibrillin-1 
and fibronectin are enriched and contribute to the prominent thickening of CADASIL 
vessel walls without co-localizing with Notch3-ECD deposits, likely as a result of fibrotic 
adaptation secondary to aggregate formation. For LTBP-1, a key regulator of the TGF-β 
signaling pathway, an accumulation as well as a striking co-localization with Notch3-ECD 
deposits is shown suggesting specific recruitment into aggregates. Furthermore, increased 
levels of the TGF-β pro-domain (also known as latency-associated peptide, LAP) were 
found implying dysregulation of the TGF-β pathway in CADASIL development. Finally, a 
direct interaction of LTBP-1 with Notch3-ECD is demonstrated and evidence for a 
co-aggregation with mutant Notch3 in vitro is provided. Conclusively, I propose LTBP-1 as 
a novel component of Notch3 deposits with a role in CADASIL pathogenesis. 
Zusammenfassung 
 
IV 
Zusammenfassung 
CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy) ist die häufigste monogen vererbte Ursache zerebraler 
Mikroangiopathien, die zu juvenilem Schlaganfall und Demenz führen. CADASIL wird 
verursacht durch Mutationen im Notch3 Transmembranrezeptor, wobei die Anzahl der 
Cysteinreste der extrazellulären Domäne (Notch3-ECD) verändert wird. Dadurch kommt 
es zu einer Multimerisierung und Ablagerung von Notch3-ECD an der Plasmamembran 
von glatten Gefäßmuskelzellen in kleineren Arterien. Diese Aggregate gelten als die 
frühste pathologische Veränderung bei CADASIL und sind verantwortlich für die 
Rekrutierung funktionell wichtiger Proteine.  
In der vorliegenden Arbeit wurden biochemische und histologische Methoden an 
Hirngewebe von CADASIL-Patienten beziehungsweise von Kontrollen angewandt sowie 
in vitro Analysen angefertigt, um die Auswirkungen der Notch3-ECD Akkumulation auf 
die extrazellulären Matrixproteine Thrombospondin-2, Fibrillin-1, Fibronectin und 
Vertreter der latent transforming growth factor-β (TGF-β) binding protein (LTBP)-Familie 
zu untersuchen. Dabei konnte gezeigt werden, dass die strukturgebenden Matrixproteine 
Fibrillin-1 und Fibronectin in den verdickten Gefäßen bei CADASIL-Patienten angereichert 
sind, jedoch nicht mit Notch3-ECD überlagern. Vermutlich handelt es sich dabei um eine 
fibrotische Anpassung sekundär zu den Notch3-ECD-Aggregaten. Für LTBP-1, welches 
den TGF-β Signalweg reguliert, wurde sowohl eine Anreicherung als auch eine 
Ko-lokalisation mit Notch3-ECD gefunden. Dies deutet auf eine spezifische Rekrutierung 
in die Notch3-ECD Aggregate hin. Darüber hinaus wurde auch eine vermehrte 
Anreicherung der TGF-β Pro-Domäne LAP (latency-associated peptide) gefunden, was auf 
eine Involvierung des TGF-β Signalweges bei CADASIL hindeutet. Abschließend zeigen in 
vitro-Versuche, dass LTBP-1 mit Notch3-ECD direkt interagiert und dadurch auch 
ko-aggregieren kann. Damit lässt sich festhalten, dass LTBP-1 als neuartige Notch3-ECD-
Aggregatkomponente identifiziert wurde, welche vermutlich maßgebend zu der 
Pathogenese von CADASIL beiträgt.  
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1 Introduction 
Stroke is the third leading cause of death worldwide only outnumbered by coronary heart 
disease and cancer (Warlow et al., 2003). Moreover, it represents the most common cause 
for long-term neurological disability entailing a high cost expenditure estimated around 
annual 64 billion Euros in Europe (Olesen et al., 2012). 
In about 20 % of the cases, strokes are hemorrhagic resulting from vessel wall rupture, 
which causes the extravasation of blood. Eighty percent of cases, however, are ischemic 
(Figure 1) as a consequence of vessel occlusion leading to a restriction of blood supply and 
a depletion of oxygen and nutrients in the tissue surrounding the site of the insult. The 
main causes underlying ischemic stroke are large-artery atherosclerosis, cardioembolism 
and cerebral small vessel disease (SVD, Figure 1) (Warlow et al., 2003). Although SVD 
accounts for only ~20 % of acute strokes (Figure 1) and its immediate effects on short-term 
disability and survival are less severe compared to other stroke subtypes, it represents the 
major cause for long-term disability and vascular dementia, the second most common form 
of dementia after Alzheimer’s disease (Warlow et al., 2003). Moreover, recent studies 
identified SVD as the most prevalent neurological disorder in aging populations and it 
represents a considerable health care problem posing an increasing burden on our society 
(Pantoni, 2010). Thus, the exploration of the molecular causes of SVD is of high importance.  
 
Figure 1: Frequency of hemorrhagic (blue) and ischemic (orange) stroke in industrialized 
countries. Ischemic stroke is further subdivided in several subtypes according to underlying causes.  
Since this thesis focuses on cerebral SVD, an introduction into the brain vascular network is 
given in the following section. 
Hemorrhagic 
stroke 
Atherosclerosis 
Cardioembolism 
Rare causes 
Small vessel 
disease  
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1.1 Cerebral vasculature 
The brain is the organ with the highest energy demand consuming roughly 20 % of the 
cardiac output (Wardlaw et al., 2013a). Due to its low storage capacities, this demand can 
only be satisfied by a constant blood supply provided by a complex brain vascular system.   
1.1.1 Brain vascular network 
Large arteries supply the brain with blood and they reach its base to form a circuit, the 
so-called circle of Willis, which separates into the three main intracranial arteries: the 
middle, anterior and posterior artery (1-10 mm diameter). At the brain surface, each artery 
branches into a wide-ranging network of small resistance arteries (0.1-1 mm diameter) and 
arterioles (20-100 µm diameter), which then submerge deeply into the brain as perforating 
arterioles (20-50 µm diameter) terminating in the white matter (Figure 2) (Pantoni and 
Garcia, 1997). This represents a unique ”outside in” vascularization pattern from the brain 
surface into the parenchyma, whereas other major organs are usually vascularized from the 
”inside out” (Iadecola, 2013).  
The basal ganglia, representing deep grey matter, are supplied by a second less extensive 
system of shorter arterial perforators, which originate directly from the circle of Willis and 
its proximal branches, the middle and posterior cerebral artery (Figure 2) (Pantoni and 
Garcia, 1997).  
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Figure 2: Schematic overview of the brain vascular system. The white matter is supplied by 
superficial perforating arterioles arising from the middle and anterior cerebral arteries. The basal 
ganglia, representing deep grey matter, are supplied by perforating arterioles diverging directly 
from the circle of Willis and its proximal branches. The two systems of perforating arterioles 
terminate in the watershed area (green circle) (adapted from Wardlaw et al., 2013a).  
In SVD, perforating arterioles of the white and deep grey matter are affected, while the 
cortex is relatively spared (Viswanathan et al., 2006). In the deepest area of the brain, the 
so-called watershed area, the vascular network is terminating and does not overlap. Since a 
systemic or focal blood flow deficit cannot be compensated by collateral branches, this 
region is especially vulnerable to injuries (Iadecola, 2013).  
1.1.2 Structure of cerebral blood vessels 
Histological analyses over the last decades have shown that SVD is associated with 
changes in arterial morphology affecting one or more of the three principal layers: the 
tunica intima, the tunica media and the tunica adventitia (Figure 3).  
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Figure 3: Structure of an arterial vessel. The tunica intima, the innermost layer, consists of a single 
layer of endothelial cells and the tunica elastic interna. The tunica media is build up by 
circumferentially arranged vascular smooth muscle cells. The external layer, the tunica adventitia, is 
composed of mainly fibroblasts and extracellular matrix. 
The tunica intima consists of a single layer of endothelial cells that are connected by tight 
junctions sealing the vessel lumen to restrict the exchange of metabolites. The basement 
membrane, a thin layer of support tissue mainly composed of collagen type IV, 
proteoglycan, hyaluronan, fibrillin and fibronectin, underlies the endothelial cells. Next, 
the tunica elastica interna, which primarily contains elastin produced by endothelial cells, 
separates the tunica intima from the tunica media. Small fenestrations in the tunica elastica 
interna allow communications between the endothelium and vascular smooth muscle cells 
(vSMCs).  
The tunica media is composed of several layers of circumferentially arranged vSMCs 
surrounded by organized layers of elastic fibers and interlamellar matrix (collagens and 
microfibrils) to increase the elasticity and strength of the vessel wall. VSMC are highly 
specialized cells, which can contract and relax to control the vessel lumen diameter and 
thereby blood flow. Capillaries lack the tunica media completely and are built up by an 
endothelial layer, basement membrane and discontinuous pericyte cell layer.  
The tunica adventitia is an assembly of loose connective tissue consisting of mainly 
collagen type I, III and VI, fibrillin-1 and fibronectin produced by fibroblasts. This 
architectural framework not only integrates the vessels into the surrounding tissue but also 
maintains its mechanical and elastic properties and retains cytokines and growth factors. 
Tunica elastica interna
Endothelial cell
Tunica intima
Tunica media
Tunica adventitia
Smooth muscle cell
Introduction 
 
8 
Additionally, other cells e.g. of the inflammatory type (macrophages and lymphocytes) can 
be present.  
1.2 Cerebral small vessel disease  
1.2.1 Sporadic form 
The term cerebral small vessel disease (SVD) describes a group of pathological conditions 
with various etiologies that affect the structure and function of perforating cerebral 
arterioles and capillaries, but also venules damaging the cerebral white and deep grey 
matter (Pantoni, 2010). SVD mostly develops unnoticed for many years before becoming 
clinically evident in form of sudden-onset stroke symptoms and/or global neurological 
dysfunction including substantial cognitive, psychiatric and physical disabilities (Wardlaw 
et al., 2013a). Since small vessels are difficult to image and investigate in vivo and clinical 
manifestations are diverse, the diagnosis of SVD remains a challenge (Wardlaw et al., 
2001).  
Despite a number of clinical studies, the pathogenesis of SVD is largely unknown 
precluding the development of new treatment options. Pathological data are mainly 
available from end-stage SVD complicating the identification of the earliest disease-causing 
events. A central aspect is hypoperfusion and ischemia mediated by narrowed arteries and 
a characteristic loss of vSMCs, which impairs adaptive responses of the vessel wall to 
changes in cerebral blood flow. However, little is known how this might cause the 
neurological and cognitive symptoms (Wardlaw et al., 2013a). Moreover, pathological 
processes are influenced by various genetic and environmental risk factors such as 
advanced age, hypertension, smoking, diabetes mellitus, hyperlipidemia and atrial 
fibrillation (Iadecola, 2013) making it difficult to determine clear cause-and-effect 
correlations. This problem of “mixed pathologies” can be at least partly circumvented by 
analyzing monogenic SVD forms with a defined etiology, which due to their early onset 
show pathologies largely independent of age effects (Dichgans, 2007). They are thus 
considered valuable model diseases to uncover biological pathways promoting vascular 
changes and to provide causal links between risk factors and dementia. 
1.2.2 Monogenic forms of cerebral small vessel disease 
Several monogenic causes of SVD forms have been identified so far (Table 1). Among them 
cerebral autosomal recessive arteriopathy with subcortical infarcts and 
leukoencephalopathy (CARASIL), retinal vasculopathy with cerebral leukodystrophy 
(RVCL) and COL4A1-related SVD are very rare conditions. Far more patients suffer from 
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cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL), the most common monogenic cause of SVD and 
vascular cognitive impairment (Joutel et al., 1996, Chabriat et al., 2009). It thus represents 
the most widely studied inherited SVD and abundant clinical data are available, making 
CADASIL a valuable model condition to study pathological processes involved in SVD 
development.  
Table 1: Overview of hereditary forms of small vessel disease.  
Disorder  
(Mode of inheritance) 
Genetic 
identity 
Characteristic clinical features 
CADASIL 
(Dominant) 
NOTCH3 Migraine, subcortical infracts, dementia, 
mood disorder 
CARASIL 
(Recessive) 
HTRA1 Subcortical infarcts, dementia, spondylosis, 
alopecia  
RVCL 
(Dominant) 
TREX1 Retinopathy, nephropathy, migraine, 
ischemic strokes, dementia 
COL4A1-related SVD  
(Dominant) 
COL4A1 Infantile hemiparesis, intracerebral 
hemorrhage, microbleeds, intracranial 
aneurysms 
CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy; CARASIL: Cerebral autosomal recessive arteriopathy with subcortical infarcts 
and leukoencephalopathy, RVCL: retinal vasculopathy with cerebral leukodystrophy; Htra1: High 
temperature requirement A1; COL4A1: Collagen type IVα1; SVD: Small vessel disease (Joutel et al., 
1996, Hara et al., 2009, Kuo et al., 2012, Richards et al., 2007). 
1.3 CADASIL 
Starting in the 1970s, a number of case reports described a hereditary cerebral disorder 
with multiple early-onset infarcts and progressive dementia in European families 
(Sourander and Walinder, 1977, Stevens et al., 1977, Sonninen and Savontaus, 1987, Davous 
et al., 1991, Tournier-Lasserve et al., 1991, Mas et al., 1992). In 1993, the acronym CADASIL 
(cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy) was coined highlighting the main characteristics of this disease 
(Tournier-Lasserve et al., 1993). Since then, more than 500 families worldwide have been 
reported. A small study from Scotland estimated the prevalence at 4.15 cases per 100 000 in 
Scotland (Razvi et al., 2005), however, the overall prevalence is unknown (Chabriat et al., 
2009). 
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1.3.1 Clinical features 
The clinical manifestations of CADASIL include a variety of neurological and 
neuropsychological aspects (Figure 4), however, four principle symptoms are considered 
central to the disease: migraine with aura, recurrent subcortical infarcts, mood disturbances 
(e.g. apathy) and cognitive impairment (Chabriat et al., 2009). The first ischemic attack 
occurs on average with ~51 years (Opherk et al., 2004). As the disease progresses, cognitive 
decline develops but may also precede the first symptomatic ischemic episodes (Amberla 
et al., 2004). Initially, executive and organizing functions are affected and patients present 
with poor concentration and general mental and psychomotor slowing and at later disease 
stages, cognitive impairment ultimately results in vascular dementia (Dichgans, 2009). 
Already by the age of 65 years, roughly 80% of the patients are demented (Kalimo et al., 
2002). 
 
Figure 4: Overview of the main clinical manifestations of CADASIL. The exact appearance of the 
first white matter abnormalities are unknown and thus represented with a dotted line (adapted from 
Chabriat et al., 2009).  
The disease progresses slowly and its aggravation is associated with recurrent strokes. 
Within a mean of 23 years after the first symptoms have occurred, CADASIL complications 
leads to death (Dichgans et al., 1998). To date, no CADASIL treatment is available except 
for the amelioration of migraine symptoms (Forteza et al., 2001). 
CADASIL patients show considerable alterations on cranial magnetic resonance imaging 
(MRI), a routine neuroimaging tool widely used in clinical practice (Wardlaw et al., 2013b). 
  Executive dysfunction               Dementia 
80 30 40 50 60 70 
Migraine with aura 
Age (years) 20 10 
Ischemic stroke 
Mood disturbances 
Apathy 
Motor disability 
White matter hyperintensities 
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Symptomatic but also asymptomatic patients display characteristic white matter 
hyperintensities (Figure 5) and their extent broadly correlates with the severity of the 
clinical status (Chabriat et al., 1998, Dichgans et al., 1998, Kalimo et al., 2002). White matter 
hyperintensities, thought to arise from axonal demyelination, increase during the course of 
the disease and their absence almost excludes this diagnosis (Chabriat et al., 1998). 
Additionally, lacunes, fluid-filled cavities of past infarcts (Figure 5), and brain atrophy as a 
result from neuronal loss are frequently observed (Dichgans et al., 1999, Peters et al., 2006, 
Duering et al., 2012, Duering et al., 2013). 
 
Figure 5: MRI scans of CADASIL patients showing characteristic white matter hyperintensities 
(arrows) (Opherk et al., 2009b). 
Based on the clinical features, a number of affected families were collected in the 1990s to 
search for the underlying gene defect.  
1.3.2 Genetics 
In 1993, Tournier-Lasserve and coworkers performed genetic linkage analysis in two 
unrelated French families and mapped the CADASIL-causing locus to chromosome 19 
(Tournier-Lasserve et al., 1993). The subsequent investigation of 13 additional families 
allowed a further refinement of the genetic interval (Ducros et al., 1996) and finally the 
identification of the critical gene, NOTCH3, on chromosome 19p13 (Joutel et al., 1996).  
NOTCH3 encompasses 33 exons and encodes a single-pass type I transmembrane receptor 
of 2321 amino acids. It belongs to an evolutionary conserved family involved in cell-cell-
mediated signaling playing essential roles in the development of multicellular organisms 
(Artavanis-Tsakonas et al., 1999). In addition, Notch receptors exert functions in adult 
animals including humans, which is reflected by their involvement in several clinical 
conditions (Penton et al., 2012). They all show the same domain organization with a large 
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extracellular domain (ECD) comprising 34 epidermal growth factor (EGF)-like repeats and 
three notch/lin-12 repeats, a transmembrane domain and an intracellular domain (Notch-
ICD) consisting of seven ankyrin repeats and a PEST motif (Figure 6). Notch proteins are 
synthesized as ~280kDa proteins which undergo three successive proteolytic cleavages 
(S1-3) (Figure 6, black arrows). 
 
Figure 6: Schematic Notch3 structure. Notch3 is composed of an extracellular domain (ECD) with 
34 epidermal growth factor (EGF)-like repeats including the ligand recognition site (LRS) in 
EGF-like repeats 10/11 (orange) and three lin-12/Notch repeats. The transmembrane domain (TM) 
is followed by the intracellular domain (ICD) comprising several ankyrin repeats and a PEST motif. 
The arrows indicate the cleavage sites S1-3. 
The S1 cleavage is mediated by a furin-like convertase in the Golgi network and occurs 
during receptor transport to the plasma membrane. The cleavage products, among them 
the 210 kDa Notch-ECD fragment, remain associated non-covalently and are presented as 
heterodimers at the cell surface (Blaumueller et al., 1997). Signaling is initiated by 
membrane-bound ligands (e.g. Delta or Serrate) on neighboring cells which interact with 
the ligand binding domain located in EGF-like repeats 10/11 of the ECD (Figure 6). This 
triggers the S2 cleavage close to the plasma membrane by TNFα-converting enzyme 
(TACE), a metalloprotease also known as ADAM-17 (Brou et al., 2000). The Notch3-ECD is 
shedded and the remaining membrane-attached fragment becomes substrate for the 
γ-secretase catalyzing processing at the S3 site, an unusual cleavage occurring within the 
plasma membrane (Mumm et al., 2000). The resulting fragment, Notch-ICD, is released and 
translocates to the nucleus where it interacts with DNA binding proteins including RBP-Jk 
to regulate transcription of target genes (Fouillade et al., 2013).  
Whereas invertebrates possess only one NOTCH gene, four isoforms are present in 
vertebrates. Notch3 plays essential roles in cell fate determinations during embryonic 
development and in adulthood (Artavanis-Tsakonas et al., 1999). It is mainly expressed in 
S
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S
2
 
S
3
 
PEST-motif 
Lin-12/Notch repeats 
Ankyrin repeats 
EGF-like repeats 
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vSMCs and pericytes regulating cell growth, migration and apoptotic death (Joutel et al., 
2000, Prakash et al., 2002, Joutel et al., 2010). Notch3 knockout mice (Notch3-/-) are viable 
and fertile demonstrating a non-essential role of the protein (Domenga et al., 2004, Belin de 
Chantemele et al., 2008). While arterial vSMCs of Notch3-/- mice are indistinguishable from 
wild type cells at birth, they have an abnormal shape and a smaller size in adult mice. 
Moreover, their reactivity to changes in arterial pressure and cerebral blood flow is 
compromised especially in small arteries (Domenga et al., 2004, Belin de Chantemele et al., 
2008).  Thus, Notch3 is believed to be required for arterial differentiation and maturation of 
vSMCs in cerebral arteries. 
NOTCH3 mutations resulting in CADASIL exclusively localize to exons 2-24 encoding the 
34 EGF-like repeats (Chabriat et al., 2009). Each repeat contains a conserved number of six 
cysteine residues forming three disulfide bridges between cysteines 1-3, 2-4 and 5-6 (Figure 
7), which are required for the correct folding of the receptor (Simpson, 1997). 95 % of 
mutations lead to a single amino acid substitution, whereas in-frame deletions and splice 
site mutations are rarely observed. Substitutions predominantly affect cysteine residues 
within individual EGF-like repeats causing either the addition or the loss of a cysteine 
(Figure 7) (Joutel et al., 1997, Peters et al., 2005b). Today, more than 150 mutations are 
known and interestingly, a hotspot is found in EGF-like repeats 3 and 4, in which ~68 % of 
the mutations reside (Joutel et al., 1997, Peters et al., 2005b). Genetic testing for pathogenic 
NOTCH3 mutations is the diagnostic gold standard, since its sensitivity is close to 100 % 
(Joutel et al., 1997).  
 
Figure 7: CADASIL mutations are highly conserved. Each EGF-like repeat bears a conserved 
number of six cysteines (orange) forming three disulfide bridges (S-S) between Cys 1-3, 2-4, 5-6. The 
lack or addition (dotted circle) leads to an odd number of cysteines. Adapted from Chabriat et al., 
2009. 
1.3.3 Pathology and pathomechanism 
The gain or loss of a cysteine residue caused by CADASIL mutations generates an 
unpaired sulfhydryl group, which likely promotes disulfide bond formation between 
mutant Notch3-ECD proteins (Duering et al., 2011). This is believed to induce the 
EGF-like repeat 
Typical CADASIL 
 missense mutations 
S-S 
S-S 
C C C C C
C C C C CC C
C C C C CC
S-S 
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extracellular multimerization of shedded Notch3-ECD molecules leading to their 
accumulation in the tunica media of vessel walls (see below) (Dichgans et al., 2000, Joutel et 
al., 2000). Notch3-ECD aggregates can be detected by immunohistological staining and are 
believed to coincide with large electron-dense deposits known as granular osmiophilic 
material (GOM, Figure 8), an invariant feature of CADASIL-affected vessels (Joutel et al., 
2000, Ishiko et al., 2006). GOM are non-amyloid, basophilic structures 0.2-0.8 µm in 
diameter (Kalimo et al., 2002, Tikka et al., 2009) mostly located in extracellular indentations 
of vSMC, but also in the thickened basement membrane. Although symptoms in CADASIL 
are exclusively neurological, GOMs can be found in vessel walls of many other organs, 
allowing diagnostic electron microscopy analysis of skin biopsies (Chabriat et al., 2009).  
 
Figure 8: Pathological Notch3-ECD aggregates and granular osmiophilic material (GOM). Left: 
Section of a white matter arteriole immunostained for Notch3-ECD, showing the characteristic 
granular Notch3-ECD deposits within the thickened vascular wall in brown. Right: Electron 
micrograph of a dermal artery showing granular osmiophilic material (arrow) at the surface of a 
vascular smooth muscle cell (courtesy of Christian Opherk, ISD). 
While both Notch3-ECD aggregates and GOM are hallmarks of CADASIL, other 
morphological changes of vessel walls are also common in sporadic SVD. They are mainly 
restricted to small perforating brain vessels in the white and deep grey matter, while the 
cortex is relatively spared. Arterioles show non-arteriosclerotic thickening of the vessel 
wall especially at the tunica intima and tunica adventitia causing luminal stenosis in 
pre-capillary arterioles (less than 50 µm diameter) (Miao et al., 2004). These fibrotic changes 
likely result from increased amounts of extracellular matrix proteins such as collagen  
type I, III, IV and VI (Miao et al., 2004, Miao et al., 2006, Dong et al., 2012), elastin (Caronti 
et al., 1998) and fibronectin (Oide et al., 2008), or debris from degenerating vSMCs (Kalaria, 
1996, Ceroni et al., 2000, Miao et al., 2004). Additionally, CADASIL patients suffer from an 
irregular distribution of vSMCs in the tunica media (Miao et al., 2004), an alteration 
Notch3-ECD aggregates 
Granular osmiophilic 
material (GOM) 
Tunica intima 
Tunica media 
Tunica adventitia 
25µm 
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possibly preceding the degeneration and loss of this cell type in later stages of the disease 
(Miao et al., 2004) (Okeda et al., 2002).  
The molecular mechanisms underlying Notch3-ECD deposit formation and the 
pathological events leading to vessel dysfunction are incompletely understood. A variety 
of studies using cultured cells have failed to detect alterations in receptor maturation and 
signaling capacity of CADASIL-mutant Notch3 (Haritunians et al., 2002, Karlstrom et al., 
2002, Joutel et al., 2004, Peters et al., 2004, Low et al., 2006). Moreover, data from several 
CADASIL mouse models using mutated NOTCH3 (Dubroca et al., 2005, Monet-Lepretre et 
al., 2009, Joutel et al., 2010, Wallays et al., 2011) strongly suggested that loss-of-function is 
not the prevalent pathomechanism, although conflicting results have been reported 
(Arboleda-Velasquez et al., 2011). Only a few mutations located within the ligand-binding 
site (EGF-like repeats 10/11), occurring in roughly 4 % of all CADASIL patients (Monet-
Lepretre et al., 2009), cause impairment in signal transduction (Joutel et al., 2004, Peters et 
al., 2004, Monet-Lepretre et al., 2009, Arboleda-Velasquez et al., 2011). However, since 
hypomorphic Notch3 allele carriers do not show signs of CADASIL pathology (Rutten et 
al., 2013), it is likely the alteration of the number of cysteines, which confers pathogenicity 
to these mutants. Thus, novel pathogenic roles for mutant Notch3 rather than 
compromised Notch3 function have been proposed as the primary determinant of the 
disease (Joutel, 2011). 
The appearance of Notch3-ECD aggregates prior to neurological symptoms in CADASIL 
patients (Mayer et al., 1999, Lesnik Oberstein et al., 2003) suggests that they represent an 
early manifestation causative for disease development. This hypothesis is supported by 
experimental data from the TgNotch3R169C mouse model, which carries a PAC (P1-derived 
artificial chromosome) clone containing the mutant (R169C) rat NOTCH3 gene driven by 
the endogenous mouse Notch3 promoter (Joutel et al., 2010). In a time-dependent fashion, 
TgNotch3R169C mice show an extracellular accumulation of Notch3-ECD (2 months), 
followed by GOM development (5 months), brain parenchyma lesions and astrogliosis  
(12 months) and progressive white matter degeneration (20 months). Since the mice do not 
display any ischemic attacks, they likely represent an early disease model. The initial 
appearance of Notch3-ECD deposits puts them at the beginning of a cascade of events 
eventually resulting in CADASIL pathology and it is currently believed that the 
co-aggregation of additional proteins is a major determinant of this process.   
While Notch3-ECD aggregation has been well studied in vivo, little is known about the 
exact nature of the aggregation process. Using scanning for intensely fluorescent targets 
(SIFT), a confocal technique, which distinguishes single protein particles from aggregated 
forms allowing the quantitative monitoring of protein multimerization in solution (Giese et 
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al., 2005), our group has recently recapitulated the Notch3-ECD aggregation process  
in vitro. A purified recombinant Notch3 fragment comprising EGF-like repeats 1-5, the 
mutational hotspot region, only showed formation of higher order multimers when 
bearing a CADASIL-causing mutation (Opherk et al., 2009a, Duering et al., 2011), a 
mechanism mediated by disulfide bond formation (Duering et al., 2011). Moreover, 
co-aggregation of thrombospondin-2 (Duering et al., 2011), a known Notch3 interactor and 
regulator of ECM assembly (Meng et al., 2009), was observed providing first direct 
experimental evidence for a pathological co-aggregation mechanism, i.e. that other proteins 
may be sequestered into aggregates.  
Further support for such a mechanism was provided by proteomic studies of both mouse 
and CADASIL patient material (Arboleda-Velasquez et al., 2011, Monet-Lepretre et al., 
2013). Clusterin and collagen18α1/endostatin were identified as GOM components in the 
tunica media of CADASIL brain vessels collected by laser capture microdissection 
(Arboleda-Velasquez et al., 2011). Monet-Lepretre and co-workers extended this approach 
by enriching Notch3-ECD deposits from CADASIL brain material and TgNotch3R169C 
vessels through sequential fractionation and analyzing the Notch-ECD-containing fraction 
(Monet-Lepretre et al., 2013). A variety of proteins predominantly from the ECM were 
found to co-fractionate with Notch3-ECD. For two of them, tissue inhibitor of 
metalloprotease 3 (TIMP3) and vitronectin, further evidence for their presence in 
Notch3-ECD aggregates was reported and disease-related roles proposed. Their abnormal 
recruitment was suggested to cause a dysregulation of their activity contributing to the 
impaired ECM homeostasis in small vessels (Monet-Lepretre et al., 2013). 
1.4 Goals of this thesis 
Notch3-ECD aggregation in CADASIL vessel walls likely represents the initiating event of 
a continuative process involving the recruitment and sequestration of ECM proteins with 
important roles in normal vessel function ultimately leading to multifactorial toxicity. 
Although initial efforts to identify co-aggregating factors have yielded a variety of 
candidate proteins, the pathological events resulting in vessel degeneration are still poorly 
understood. This thesis aimed to extend and refine previous data on Notch3-ECD 
aggregate components by analyzing potential candidate proteins in more detail. Due to the 
extracellular localization of Notch3 deposits and the crucial role the ECM plays in vessel 
homeostasis, five ECM and ECM-associated (matricellular) proteins were selected for this 
study: fibrillin-1 and fibronectin, two major structural ECM components; LTBP-1 and 
LTBP-4, two members of the latent transforming growth factor-β (TGF-β) binding protein 
(LTBP) family of TGF-β signaling regulators; and thrombospondin-2 (TSP-2), a 
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matricellular protein known to interact with Notch3 and to co-aggregate with CADASIL 
mutants. Approaches applied in this study include biochemical fractionation and 
immunohistochemical localization on CADASIL patient brain autopsy material as well as 
in vitro interaction and co-aggregation assays. Using these techniques, I sought to provide 
an in depth analysis of the roles ECM proteins play in Notch3-ECD deposition.  
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2 Materials and Methods 
2.1 Equipment 
37 °C incubator (Function line) Heraeus 
37 °C shaker (Certomat BS-1) Sartorius 
Agarose gel chamber (40-0708) PEQLAB 
Autoclave (VX 150, DX 65) Systec 
Cell culture CO2 incubator (HERA Cell) Heraeus 
Cell culture flasks for purification (Nunclon Surface Triple 
Flasks 500cm2) 
Nunc 
Cell Strainer (40 µm) BD Falcon 
Centrifuge (Avanti J-26 XP) with swinging rotor (JS 7.5) Beckmann Coulter 
Clean bench (HeraSafe KS18) Heraeus 
Cooling centrifuge for small disposable tubes (5417R) Eppendorf 
Cooling centrifuge for large disposable tubes (Heraeus 
Megafuge 16R) 
Thermo Scientific 
Cooling Ultracentrifuge (Optima L-90K) Beckman Coulter 
Coverslides 22x50 mm #1 (Inverse microscopy) Menzel Glas 
Coverslides 24x60 mm # 1.5 (confocal microscopy) Menzel Glas 
Disposable Cell culture flasks T80 Nunc 
Disposable Cryotube (1.8 mL) Nunc 
Disposable Culture well plates (6 and 24 well) BD Falcon 
Disposable tubes (0.5 ml; 1.5 ml; 2.0 ml) Eppendorf 
Disposable tubes (15 mL) Thermo Scientific 
Disposable tubes (50 mL) BD Falcon 
Disposable well plate for protein determination  
(96well Microplates PS, F-bottom) 
Greiner bio-one 
Electrophoresis cell (Mini-PROTEAN) BioRad 
Freezer -80° C (Hera Freeze Top) Thermo Scientific 
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Homogenisator Tissue Lyser LT Qiagen 
Liquid Nitrogen Tank (Cryoplus 2) Thermo Scientific 
Microscope Axiovert 200M; Camera AxioCam MRm Zeiss 
Microscope slide (Superfrost Plus) Menzel 
Microscope, confocal (TCS SP5) Leica 
Microwave Siemens 
Needle with cannula (0,33x12 mm, Myjector U40) Terumo 
pH-Meter (Lab 850) Schott Instruments 
Power Supply (Power Pac 30) PEGLAB 
Rocking Shaker (ST5 CAT) neoLab 
Tissue grinder, Type Potter-Elvehjem with smooth pestle Wheaton 
Water bath (1005) GFL 
2.2 Chemicals  
0,05 % Trypsin-EDTA Gibco 
2-Mercaptoethanol (β-ME) ≥ 99,0 % Sigma 
Acetone Merck 
Acrylamide: Ultra Pure Proto Gel (30 %) 
37.5:1 Acrylamide/Bisacrylamide 
National diagnostics 
Agarose Sigma 
Albumin from bovin serum (BSA) 96 % Sigma 
Ammoniumpersulfat (APS) Sigma 
Ampicillin Sigma 
Boric acid Sigma 
Bromphenol Blue Sigma 
Protease inhibitor (complete Mini EDTA free cocktail tablets) Roche 
Dimethyl Sulfoxide (DMSO) Sigma 
Disodiumphosphate (Na2HPO4) Merck 
DMEM + GlutaMAX Invitrogen 
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Ethylenediaminetetraacetic acid disodium (EDTA) Roth 
Ethanol 70 %; 96 % Roth 
Ethanol absolute, for analysis Merck 
Fetal Bovine Serum (FBS) Gibco 
Ficoll PM 400 Sigma 
G418 Sulfate Calbiochem 
Glycerol ≥99,5 % Roth 
Glycin Sigma 
Hydrogen peroxide (H2O2) 30 % Merck 
Methanol ≥ 99% Roth 
Monopotassium phosphate (KH2PO4) Merck 
Orange G Sigma 
Paraformaldehyd (PFA) 4 % in PBS 7.4 Morphisto 
Penicillin/Streptomycin (10000U/mL) Invitrogen 
Peptone (from Soja) Roth 
Select agar Invitrogen 
Skim milk powder Fluka 
Sodium bicarbonate (NaHCO3) Sigma 
Sodium chloride (NaCl) Roth 
Sodium dodecyl sulfate (SDS) Pellets Serva 
Tetramethylethylenediamine (TEMED) Roth 
Tri-Sodiumcitrat-dihydrat (Na3C6H5O7xH2O) Roth 
Tris (Tris(hydroxymethyl)-Aminomethane) Merck 
Trizma base Sigma 
Tween 20 Roth 
Xylene Cyanole F.F ICN 
Xylol (Rotihistol) Roth 
Yeast extract Roth 
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2.3 Recombinant Proteins 
Fibronectin Sigma 
Human IgG1-Fc R&D Systems 
Human Notch3-Fc Chimera, aa 40-467 R&D Systems 
2.4 Human samples 
2.4.1 Human brain tissue 
Brain samples from twelve deceased elderly patients, frozen or paraffin-embedded, were 
obtained from various sources (Brain-Net, LMU, Munich [Thomas Arzberger]; INSERM 
Paris [Anne Joutel]; Leiden University Medical Center [Saskia Lesnik-Oberstein]). A total of 
six CADASIL patients, genetically confirmed (mean age 64,3 years) and six age- and 
sex-matched controls (mean age 61,3 years) were employed. 
Table 2: Overview of all brain autopsies 
Description Sex Age Diagnosis Mutation Location 
CAD 1 M 64 CADASIL R110C Gyrus frontalis medius  
CAD 2 F 66 CADASIL D239_D253del Gyrus frontalis medius  
CAD 3 M 68 CADASIL C144S Gyrus frontalis medius  
CAD 4 F 60 CADASIL R153C Frontal lobe 
CAD 5 F 70 CADASIL C1261R Frontal lobe 
CAD 6 F 58 CADASIL R153C Frontal cortex 
Ctrl 1 M 61 Control - Gyrus frontalis medius  
Ctrl 2 F 55 Control - Gyrus frontalis medius  
Ctrl 3 F 60 Control - Gyrus frontalis medius  
Ctrl 4 F 73 Control - Gyrus frontalis medius 
Ctrl 5 M 60 Control - Gyrus frontalis medius 
Ctrl 6 F 59 Control - Gyrus frontalis medius 
 
2.4.2 Brain vessel isolation 
Phosphate buffered saline (PBS)  
154 mM NaCl, 9.5 mM Na2HPO4, 1.7 mM KH2PO4, pH 7.4 
50 mg brain tissue was homogenized with 15 mL cold Minimum Essential Media (MEM, 
Invitrogen) in a tissue grinder with a total of 60 up and down strokes. An equal volume of 
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30 % Ficoll in MEM was added and centrifuged at 6000 g, 4 °C for 20 min in a swinging 
rotor. The supernatant was discarded and the pellet suspended in 1 %BSA in PBS. Next, 
the homogenate was poured onto a 40 µm Nylon mesh (Corning Life Sciences) and 
extensively washed with PBS. By inversion of the nylon mesh, vessels were collected in a 
tube and pelleted for 5 min at 3000 g. The purity of the vessels was checked under a phase-
contrast microscope.   
2.5 DNA Techniques 
2.5.1 Plasmids 
Table 3: List of plasmids. EGF: epidermal growth factor, aa: amino acids.  
Plasmid Description 
Reference /  
Cloning Strategy 
pcDNA3.1 (-) Mammalian expression vector Invitrogen 
pcDNA3_LTBP-1 
Encodes human full length LTBP-1S 
with a CD5 signal peptide, 
an N-terminal HA-tag and a 
C-terminal V5-His tag 
Nathalie Beaufort, ISD 
Munich 
pSignal_LTBP-
1ΔN_HA 
Encodes N-terminally truncated 
LTBP-1 (aa 528-1395) with a 
C-terminal HA-tag 
Jorma Keski-Oja, Helsinki, 
Finland (Saharinen et al., 
1996)  
pcDNA3_LTBP-
1ΔN_V5 
Encodes LTBP-1ΔN with a 
C-terminal V5-His tag 
Generated by restriction 
with SnaBI and BbvCI of 
LTBP-1 (Vector) and LTBP-
1ΔN_HA (Insert) 
pTT5_N3EGF1-5 
Wt_Halo 
Encodes hNotch3 EGFR 1-5 with  
a Halo fusion Tag 
Patrizia Hanecker, ISD 
Munich 
pTT5_N3EGF1-5 
C183R_Halo 
Encodes hNotch3 EGFR 1-5 with 
a Halo fusion Tag, mutation C183R 
Patrizia Hanecker 
pcDNA3_LTBP-
1ΔC_V5 
Encodes a C-terminally truncated 
LTBP-1 (aa 1-689) with a C-terminal 
V5-His tag 
Nathalie Beaufort 
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2.5.2 Agarose gel electrophoresis 
Agarose Gels: 
1 % (w/v) agarose in 1xTBE buffer, melted in a microwave  
5x TBE buffer: 
445 mM Trizma base, 445 mM boric acid, 10 mM EDTA, pH 8.0  
6x DNA-loading buffer: 
60 % (v/v) Glycerol, 10 mM Tris-HCl pH 7.6, 60 mM EDTA, 2.5 mg Xylene Cyanol, 2.5 mg Orange G 
DNA fragments mixed with DNA-loading buffer were separated on a 1 % agarose Gel in 
1x TBE buffer with the addition of SYBR Safe DNA Gel Stain (Invitrogen) diluted 1:10000, 
using a constant voltage of 80 V for roughly 1 h. As a molecular marker, PeqGOLD DNA 
Ladder-Mix (PEQLAB) was used. Finally, gels were visualized on a gel-doc Fusion FX7 
(Vilber Lourmat). 
2.5.3 Restriction enzyme treatment 
Restriction enzymes (New England Biolabs): 
SnaBI (5U/µL), BbvCI (2U/µL)  
Restriction Enzyme Buffer (New England Biolabs): 
NEB4  
100x BSA (New England Biolabs): 
diluted 1:10 
Analytical restriction analysis was carried out in the following manner.  
Table 4: Analytical restriction enzyme treatment 
Component Volume 
Restriction enzyme 5 U 
Restriction buffer 3 µL 
DNA 0.6 µg 
10x BSA 3 µL 
H20 ad 30 µL 
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Preparative restriction analysis for subsequent cloning experiments was carried out in the 
following manner  
Table 5: Preparative restriction enzyme treatment 
Component Volume 
Restriction enzyme 10 U 
Restriction buffer 5 µL 
10x BSA 5 µL 
DNA 4 µg 
H20 ad 50 µL 
All restriction digestion mixtures were incubated for 1 h at 37 °C. Afterwards, the DNA 
fragments were separated on an agarose gel, extracted and purified using the GeneJET Gel 
Extraction Kit (Fermentas) according to manufacturer’s specifications.  
2.5.4 Vector dephosphorylation 
Phosphatase (New England Biolabs): 
Antarctic Phosphatase (5 U/µL)  
Phosphatase buffer (New England Biolabs): 
10x Antarctic buffer 
Table 6: Dephosphorilation of the vector 
Component Volume 
Gel extract 20 µL 
10x Antarctic buffer 3 µL 
Antarctic phosphatase 1 µL 
H20 6 µL 
In order to dephosphorylate the vector to prevent self-ligation, the gel extract was treated 
with a phosphatase for 30 min at 37 °C, followed by 5 min at 65 ° C to inactivate the 
enzyme. 
2.5.5 DNA Ligation 
Enzyme (New England Biolabs): 
T4 DNA ligase (400 U/µL) 
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Buffer (New England Biolabs):  
10x T4 DNA Ligase Reaction buffer 
Table 7: DNA Ligation Mixture 
Component Volume 
Vector 150 ng 
Insert 50 ng 
T4 Ligase 1 µL 
T4 buffer 2 µL 
H20 ad 20 µL 
Components to ligate vector and insert were mixed together and incubated 1 h at room 
temperature. 2 µL of the ligation mix was used for the subsequent transformation of 
competent bacteria. 
2.5.6 Transformation of competent bacteria 
LB-Medium: 
0.5 % (w/v) Yeast extract, 1 % (w/v) Peptone, 0.5 % (w/v) NaCl, pH 7.0; autoclaved  
LB Agar plates containing ampicillin: 
LB Medium, 0.15 % (w/v) agar, autoclaved, 100 µg/mL ampicillin is added after chilling to roughly 
50 °C. 
2 µL ligation mix was added to 50 µL of competent bacterica (E.coli DH5α, present in the 
laboratory) and incubated for 30 min on ice. A heat shock at 42 °C for 90 sec allowed the 
plasmid to permeate into bacteria. After cooling down for 2 min on ice, 250 µL LB-Medium 
was added and incubated at 37 °C for 1h under gentle agitation. Subsequently, 200 µL 
transformation mix were plated on LB Agar plates containing ampicillin. After incubation 
overnight at 37 °C, several colonies were picked from the plates in 5 mL LB-Medium + 
100 µg/mL ampicillin for small-scale DNA isolation.  
2.5.7 DNA Isolation of bacteria 
5 mL of transformed bacteria were used for small-scale DNA isolation with the NucleoSpin 
Plasmid Kit (Macherey-Nagel). The concentration and quality was checked using the 
Nanodrop ND-1000 (PEQLAB). Before the plasmid was sent for sequencing to GATC 
Biotech AG (Konstanz, Germany), analytical restriction analysis was carried out to ensure 
the correct buildup of the plasmid.  
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For large-scale DNA isolation, small amounts of transformed bacteria were diluted in 
100 mL LB-Medium + 100 µg/mL ampicillin and cultured overnight while shaking. On the 
next day, plasmid DNA was isolated with the aid of the NucleoBond Xtra Midi Kit 
(Macherey-Nagel). Again, purity and concentration was analyzed using the Nanodrop.  
2.6 Cell Culture  
2.6.1 Cell lines 
Table 8: List of cell lines. All cell lines were available in the laboratory. DMEM: Dulbecco’s 
Modified Eagle Medium 
Cell line Description Culture Medium+ 
HEK293T 
Human embryonic kidney 
cells, expressing the SV40 
large T antigen 
DMEM+GlutaMax +10% FBS + 5 mL 
Penicillin/Streptomycin 
HEK293E 
Human embryonic kidney 
cells, transfected with the 
Epstein Barr Virus nuclear 
antigen 1 (EBVNA 1) 
DMEM+GlutaMax +10% FBS + 5 mL 
Penicillin/Streptomycin + 25 µg/mL G418 
 
2.6.2 Cell Cultivation 
Cells were cultured in their respective media (see Table 8) as adherent monolayers at 37 °C 
in a humidified atmosphere of 5 % CO2. As requested, cells were passaged twice a week. 
Therefore, cells grown to 70-80 % confluency were washed once with PBS, trypsinized and 
seeded in fresh medium after resuspending in the desired ratio (roughly 1:10). Microscopic 
analysis guaranteed the condition of the cells. Frequent analysis for microplasma using the 
Venor GeM One-Step Detection Kit for endpoint PCR (Minerva Biolabs) secured a 
microplasma-free environment.   
2.6.3 Cell transfection for conditioned media 
HEK293T cells were seeded into well plates in a defined number, totaled using an 
automated cell counter (TC20, Biorad). Transfection was performed with the Fugene HD 
Transfection Reagent (Roche) according to the manufacturer’s manual. Briefly, plasmid 
and Fugene were mixed in OptiMEM (Invitrogen) and, after an incubation period of 
15 min, added to serum-free medium. Following culturing in serum-free DMEM for 48 h, 
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the medium was collected and centrifuged 10 min at 1000 g to eliminate cell debris. Finally, 
the conditioned medium was stored at -20°C until further use. 
2.6.4 Cell cryoconservation 
Freezing Medium 
FBS containing 10 % (v/v) DMSO 
90 % confluent cells grown in a T 80 flask were trypsinized and pelleted. Pellets were 
re-suspended in freezing medium, transferred into a cryotube and allowed to gradually 
freeze in a Freezing Container (Mr. Frosty, Nalgene) kept in a - 80 ° freezer overnight. On 
the next day, cryotubes were transferred into a liquid nitrogen tank for long-term storage.  
For thawing, cryotubes were allowed to quickly reach 37 °C in a water bath and 
subsequently collected in fresh medium. After centrifugation, the pellet was washed once 
with PBS and resuspended in fresh medium. Next, cells were transferred into a flask and 
allowed to sediment.  
2.6.5 Large scale transfection for protein purification 
First, two confluent T 80 flask of HEK293E cells were trypsinized and transferred into a 
triple flask with 90 mL of fresh medium. A total of four triple flasks for each purification 
were used. For the transfection on the next day, 75 µg plasmid and 300 µg poly-
ethylenimine (Polyscience) in OptiMEM were prepared for each flask and incubated for 
25 min. In the meantime, cells were washed twice with PBS. The transfection mix was 
added to 90 mL of fresh DMEM + 10 % FCS. Five hours later, cells were washed again 
twice and replaced by 90 mL serum-free medium. Conditioned medium from cells 
transfected with LTBP-1ΔC_V5 and LTBP-1ΔN_V5 was collected two or three days later, 
respectively and cleared from cell debris by centrifugation for 10 min at 1000 g. 
Afterwards, conditioned media were immediately subjected to dialysis. 
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2.7 Protein analysis 
2.7.1 Antibodies 
Respectively, Table 9 and Table 10 list all the primary and secondary antibodies that were 
used during this thesis.  
Table 9: List of primary antibodies. WB: Western Blot; IF: Immunofluorescence, IHC: 
Immunohistochemistry, SPBA: Solid phase binding assay. 
Antibody Type Application Source/Reference 
Anti-APP A4 Mouse monoclonal WB 1:4000 Millipore 
Anti-Collagen type IV Goat polyclonal IF 1:500 Southern Biotech 
Anti-fibrillin-1 Rabbit polyclonal, 
affinity purified 
IF/IHC 
1:100 
WB 1:1000 
Lynn Sakai 
(Gayraud et al., 2000) 
Anti-fibronectin Mouse monoclonal IHC 1:300 Sigma 
Anti-fibronectin Rabbit polyclonal, 
affinity purified 
WB 1:10000 Sigma 
Anti-LAP TGF-β1 Goat polyclonal WB 1:500  
IHC 1:50 
R&D Systems 
Anti-LTBP-1 Mouse monoclonal WB 1:500  
IF 1:50  
SPBA 1:500 
R&D Systems 
Anti-LTBP-4 Rabbit polyclonal  WB 1:1000 Lynn Sakai, Portland, 
USA (Ono et al., 2009) 
Anti-Notch3-ECD (2G8) Rat monoclonal 
hybridoma supernatant 
IF/IHC 1:10 Elisabeth Kremmer, 
Helmholz Zentrum, 
Munich 
Anti-Notch3-ECD (3G6) Rat monoclonal 
hybridoma supernatant 
WB 1:20 Elisabeth Kremmer, 
Helmholz Zentrum, 
Munich 
Anti-α-SMA Mouse monoclonal, 
Cy3 (red) coupled 
WB 1:10000 SIGMA 
Anti-TSP-2 Mouse monoclonal WB 1:1000 Santa Cruz 
Anti-β-Tubulin Mouse monoclonal, 
ascites fluid 
WB 1:1000 Sigma 
Anti-V5 Mouse monoclonal SPBA 1:500 
WB 1:1000 
Invitrogen 
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Table 10: List of secondary antibodies. HRP: Horseradish peroxidase. 
Antibody Type Conjugate Application Source 
Donkey anti-goat Purified Cy2 (green) IF 1:200 Jackson 
ImmunoResearch 
Donkey anti-goat Purified, F(ab')2 
Fragment 
Rhodamine 
Red X (red) 
IF 1:100 Jackson 
ImmunoResearch 
Donkey anti-mouse Purified, F(ab')2 
Fragment 
Rhodamine 
Red X (red) 
IF 1:50-1:100 Jackson 
ImmunoResearch 
Donkey anti-rabbit Purified Cy3 (red) IF 1:100 Jackson 
ImmunoResearch 
Donkey anti-rabbit Purified, F(ab')2 
Fragment 
AF488 (green) IF 1:50 Jackson 
ImmunoResearch 
Donkey anti-rat Purified, F(ab')2 
Fragment 
Cy3 (red) IF 1:50 Jackson 
ImmunoResearch 
Goat anti-mouse Polyclonal, 
purified 
Biotinylated IHC 1:200 Vector 
Goat anti-mouse Polyclonal HRP WB 1:5000-
1:10000  
SPBA 1:1000 
DAKO 
Goat anti-rabbit Polyclonal HRP WB 1:5000-
1:10000 
DAKO 
Goat anti-rabbit Polyclonal, 
purified 
Biotinylated IHC 1:200 DAKO 
Goat anti-rat Purified Fluorescein 
(green) 
IF 1:50 Jackson 
ImmunoResearch 
Horse anti-goat Polyclonal 
purified 
Biotinylated IHC 1:200 Vector 
Rabbit anti-goat Polyclonal HRP WB 1:5000 DAKO 
Rabbit anti-human Polyclonal HRP SPBA 1:1000 DAKO 
Rabbit anti-rat Polyclonal HRP WB 1:5000 DAKO 
Rabbit anti-rat Polyclonal, 
purified 
Biotinylated IHC 1:200 DAKO 
 
2.7.2 Sequential protein extraction 
Tris Buffer: 
0.05 M Tris-HCl pH 7.5 + Protease inhibitors 
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SDS Buffer: 
Tris Buffer + 1 % (w/v) SDS + Protease inhibitors 
β-ME Buffer 
SDS Buffer + 5 % (v/v) β-ME + Protease inhibitors 
5x Lämmli buffer: 
375 mM Tris Base pH 6.8, 30 % (v/v) Glycerol, 6 % (w/v) SDS, 0.03 % (w/v) Bromphenol blue  
All steps were carried out at 4 °C. 30 mg brain tissue or purified brain vessels were 
homogenized in a tissue homogenisator with a 5 mm metal-ball (Qiagen) for 3 min at 50 Hz 
in 100 µL Tris Buffer. After spinning down for 5 min at 13200 rpm, the “Tris-faction” was 
set aside and the pellet resuspended in 100 µL SDS Buffer. After lysing 30 min on ice, the 
homogenate was sedimented for 30 min at 13200 rpm. The supernatant (SDS fraction) was 
collected and the remaining pellet was further solubilized in 100 µL β-ME Buffer for 30 min 
on ice while passing though a 29 gauge needle at least 5 times. Repeated centrifugation for 
30 min at 13200 rpm resulted in the last fraction, the “β-ME fraction”. After the protein 
amount of the Tris and SDS fraction was determined, the samples were mixed with the 
appropriate amount of Lämmli-buffer. Due to the high amount of reducing agent, a protein 
determination in the β-ME fraction was not possible. 
2.7.3 Protein Quantification  
The Tris, as well as the SDS fraction of the sequential protein extraction were quantified 
using a bicinchoninic acid assay (Thermo Scientific) with a BSA standard (Quick Start BSA 
Assay, BioRad) according to the manufacturer’s protocol.   
2.7.4 Dialysis of conditioned media 
Before conditioned medium was purified, it was fist dialyzed twice against 0.5x PBS for 
one hour and another two times against 0.5x PBS + 200 mM NaCl for one hour each. 
2.7.5 Purification of proteins using Talon beads 
Talon Wash buffer 
50mM Phosphate, 300mM NaCl, pH 7.0 
The following steps were carried out at room temperature and 4 °C for LTBP-1ΔC and 
LTBP-1ΔN, respectively. To the total amount of conditioned medium (360 mL), 2 mL (bead 
volume) TALON affinity resin (Clontech), washed three times with Talon washing buffer, 
was added and allowed to bind His-tagged proteins for one hour under gentle agitation. 
Materials and Methods 
 
31 
Subsequently, the beads were spinned down for 10 min at 800 g, the supernatant was 
discarded and the beads were transferred onto a TALON 2 mL disposable gravity column 
(Clontech). After washing several times with Talon washing buffer, with and without 
adding 5mM imidazole (Fluka), the protein was eluted in PBS containing 100 mM EDTA in 
ten fractions. Protein amounts were evaluated using the Qubit protein assay (Life 
Technologies) according to the manufacturer’s instructions. To check the protein quality, 
the samples were run on a SDS-PAGE and visualized by silver staining.  
2.7.6 Solid-phase binding assay 
5x Lämmli + β-ME 
5x Lämmli + 5 % (v/v) β-ME 
20 µg/mL recombinant proteins dissolved in PBS were coated onto Maxisorp 96-well 
plates (Nunc) overnight at 4 °C. On the next day, the wells were first washed four times 
with 300 µL PBS, blocked with 1 % BSA in PBS for 1 hand then washed again. Next, 50 µL 
conditioned media from HEK293T transfected cells (LTBP-1, LTBP-1ΔC_V5, or LTBP-
1ΔN_HA) or 2 ng/µL purified LTBP-1ΔC_V5 was added for 1 h at room temperature. 
Mock transfected cells or PBS was used as a negative control. After washing, bound protein 
was detected with the appropriate first antibody (anti-V5 (detection of LTBP-1 with LTBP-
1_∆C) or anti-LTBP1 (detection of LTBP-1 with LTBP-1_∆N) and secondary antibody (anti-
mouse-HRP) diluted in PBS and sequentially added for 1 h at room temperature with an 
in-between washing step. Immune complexes were determined by incubation with TMB 
substrate solution (KPL) followed by the appropriate stop solution once the colorimetric 
reaction was visible. The optical density was measured at 560 nm and corrected with a 
measurement at 420 nm. For the calculation of the results, the unspecific binding was 
subtracted.  
To recover bound proteins from the plate, 25 µL 1xLämmli + β-ME was added to the plates 
and heated for 15 min at 95 °C.  
2.7.7 SDS-PAGE 
10x Running buffer 
0.25 M Tris, 1.92 M Glycin, 1 % (w/v) SDS  
4x Lower Tris 
1.5 M Tris pH 8.8, 0.4 % (v/v) SDS  
4x Upper Tris 
0.5 M Tris pH 6.8, 0.4 % (v/v) SDS  
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Proteins were separated using the sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) in a discontinuous system with a stacking and a separation gel 
in 1x running buffer. Table 11 shows the composition of these gels. 6 µL Precision Plus 
Protein All Blue Standards (BioRad) or 2 µL Precision Plus Protein Unstained Standards 
(BioRad) were used as molecular weight markers in case of further processing for Western 
Blots or silver staining, respectively. Electrophoresis was carried out using the minigel 
system (BioRad) at 80-120 V.   
Table 11: Composition of two 1.0 mm stacking and separation gels. AA: acryl–bisacrylamide; Tris: 
tris(hydroxymethyl)aminomethane; TEMED: tetramethylethylenediamine; APS: ammmonium 
persulfate. 
Solution  Stacking gel   Separation gel 
H20 5.88 mL 2.94 mL 
40 % AA 3 mL 0.55 mL 
4x Lower Tris - 3 mL 
4x Upper Tris 1.02 mL - 
APS 45 µL 100 µL 
TEMED 4.5 µL 10 µL 
 
2.7.8 Western Blotting 
Blotting buffer  
25 mM Tris, 192 mM Glycine, 20 % (v/v) Methanol 
10x TBST 
100 mM Tris pH 8.0, 1.5 M NaCl, 0.5 % (v/v) Tween 20  
Blocking solution 
4 % (w/v) skim milk powder in 1xTBST 
After SDS-PAGE, proteins were transferred onto a Immobilon-P Transfer Membrane 
(Millipore) in blotting buffer with a constant current of 125 mA limited to 25 V for 60-
90 min using the semi-dry system (Trans-Blot SD Semi-Dry Transfer Cell, BioRad). 
Afterwards, unspecific binding sites were inhibited in blocking solution for one hour at 
room temperature followed by incubation with the primary antibody in blocking solution 
under constant rotation at 4 °C overnight. The next day, spare antibody was removed by 
several washing steps using 1xTBST followed by incubation with the with horseradish 
peroxidase (HRP)–conjugated secondary antibody diluted in blocking solution for at least 
one hour. Subsequently, membranes were washed again in 1xTBST before developing with 
Immobilon Western Chemiluminescent HRP Substrate (Millipore) according to the 
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manufacturer’s specifications. The chemiluminesence signal was digitalized using the 
Fusion camera for the required amount of time. 
2.7.9 Silver staining 
Silver staining was performed with the Roti-Black P Silver Staining Kit (Roth) as specified 
in the manufacturer’s manual. 
2.7.10 Histological stainings 
2.7.10.1 Immunofluorescence on human Cryosections 
Histo blocking buffer 
5 % (v/v) normal donkey serum (Jackson ImmunoResearch) in PBS 
Human tissue samples were cut on a Cryostat (CM1950, Leica) in 10 µm thickness and 
stored at -80 °C until further use. On the day of the experiment, sections were thawed to 
room temperature for 15 min. Tissue was either fixed for 10 min in ice–cold acetone 
followed by air-drying for 30 min or with PFA under gentle agitation for 15 min. 
Subsequently, sections were washed 3x5 min with PBS. Thereafter, unspecific binding sites 
were blocked with histo blocking buffer for 40 min at room temperature and primary 
antibodies were diluted in histo blocking buffer and incubated overnight at 4 °C. On the 
following day, sections were first washed, incubated with the secondary, fluorescence 
coupled antibody in Histo blocking buffer for 1 h at room temperature in the dark and then 
washed again. Afterwards, sections were mounted in ProLong Gold antifade reagent (Life 
Technologies) with coverslips and sealed with common nail polish to prevent exsiccation. 
Sections were analyzed either on a confocal or inverse microscope. As an appropriate 
negative control, the first antibody was omitted in each experiment.  
2.7.10.2 AEC Staining of human paraffin sections 
Citrate buffer 
10 mM Na3C6H5O7xH2O in PBS, pH 6.0 
Paraffin sections with a thickness of 8 µm, received from Thomas Arzberger (Brain-Net, 
LMU Munich), were first deparaffinized (2x5 min Xylol) and rehydrated in a descending 
alcohol series (2 min absolute ethanol, 2 min 96 % ethanol, 2 min 70 % ethanol, 5 min PBS). 
Afterwards, sections were boiled in citrate buffer for 30 min at 95 °C to unmask antigens. 
Slides were allowed to reach room temperature, washed 2x5min in PBS and nonspecific 
binding sites were blocked for 1 h in histo blocking buffer at room temperature. Thereafter, 
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primary antibodies were diluted in histo blocking buffer and incubated overnight at 4 °C. 
The next day, slides were first washed 3x10 min in PBS. Afterwards, endogenous 
peroxidases were blocked by incubation with 0.3 % hydrogen peroxide (v/v) in PBS. 
Sections were washed and appropriate biotinylated secondary antibody diluted in Histo 
blocking buffer were applied to sections and incubated for 1 h at room temperature. After 
washing, immunoreactivity was visualized with avidin/biotin-horseradish peroxydase 
complex (Vectastain ABC-HRP kit, Vector Laboratories) and developed with 3-amino-9-
ethylcarbazole (AEC Peroxidase substrate Kit, Vector Laboratories). After washing 5 min in 
tap water, sections were counterstained with Mayer’s hematoxylin Solution (Sigma) for 
1 min to provide cytological detail and rinsed 10 min in tap water before mounting with 
ProLong Gold. Omission of primary antibodies served as a negative control. Sections were 
analyzed using a histology microscope (Zeiss). 
2.7.11 Labeling of purified proteins for SIFT 
SIFT buffer 
50 mmol/l Tris HCl, pH 7.5 
Prior to labeling the purified proteins (1.7 µM and 1.58 µM LTBP-1ΔC; 2.27 µM LTBP-1ΔN), 
samples were concentrated to 50 µL using a centrifugational filter device with a 3 kDa 
molecular cutoff (Amicon Ultra Centrifugal Filters-0.5 mL 3K, Millipore) according to the 
manufacturer’s specifications. Afterwards, green fluorescence dye (Alexa Fluor 488 
carboxylic acid succinimidyl ester, Invitrogen) was added in 2.5 fold excess, which 
covalently binds to free amines of the protein. To buffer the reaction, 100 mmol/L sodium 
bicarbonate (pH 8.5) was added and the mixture was incubated overnight at 4 °C in the 
dark.  
On the next day, the unbound dye was removed by two gel filtration steps (Zeba desalt 
spin Columns, 0.5ml, Thermo Scientific) carried out according to the manufacturer’s 
protocol. At the same time, the buffer was exchanged from PBS+EDTA to the SIFT buffer. 
Purity was checked using fluorescence correlation spectroscopy autocorrelation 
measurements (Insight Reader, Evotec-Technologies). All samples had roughly the same 
amount 70 %of unbound remaining dye. Finally, samples were aliquoted (4 µL), shock 
frozen in liquid nitrogen and stored until further use at -80 °C.  
2.7.12  Scanning for intensely fluorescent targets (SIFT) 
Scanning for intensely fluorescent targets (SIFT) is a method where single protein particles 
can be distinguished from aggregated proteins in a subpicomolar concentration. The 
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samples are composed of two proteins, one labeled in red, one in green, or a single protein 
with half of the molecule marked in red and the other half in green. The setup is confocal 
and the sample in a 398 well plate is excited by two lasers (green: 488 nm; red: 633 nm). 
They lasers are directed by an oscillating and moving beamsplitter and a moving sample 
table. The locomotion is necessary to achieve a higher sensitivity since aggregated proteins 
with a lager particle size are moving with a decreased diffusion rate. The emitted photons 
of each color are detected and represented in a two-dimensional (2-D) intensity distribution 
histogram (Figure 9). Each well is scanned 5 times and the detected fluorescence intensity 
of all measurements is summed up. Shown are particle brightness’ for each fluorophore on 
the individual axis (x-axis in green; y-axis in red) in 0-250 photons/bin in dots. A bin is the 
sum of photons that are detected in a timeframe, here 40 µsec, in which the total 
measurement time is divided. Monomers with low particle brightness are found on the 
arbitrary origin while multimers and aggregates have higher bins thus are further away 
from this point. Mono-colored aggregates are found alongside the axis while dual colored 
aggregates are found in the middle of the histogram. 
 
Figure 9: Schematic representation of SIFT data evaluation with a 2-D histogram. The y-axis 
shows photons/bin for the red channel while the x-axis represents green photons/bin. Monomers 
are located in the lower left corner. Higher order multimers of one color are distributed along the 
axis and multimers of both colors in the middle of the histogram.  
After thawing aliquots, unspecific aggregates from the freezing process were removed by 
ultracentrifugation. Therefore, 4 µL samples were diluted with 100 µL SIFT buffer and 
centrifuged for 1 h at 100000 g at 4 °C. Particle amounts were checked using fluorescence 
correlation spectroscopy autocorrelation measurements and adjusted.  
For spontaneous aggregation experiments, 50 µL of red-labeled protein was combined with 
50 µL of green-labeled protein and samples were incubated for 24 hours at 37 °C and 
500 rpm. Purified and green- or red-labeled Notch3EGF1-5 Wt or C183R were kindly 
provided by Patrizia Hanecker (ISD, Munich). Before the measuring on the SIFT Insight 
reader, 3 µL of sample was diluted in 20 µL SIFT buffer in a 384-well measurement plate 
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(Sensoplate, Greiner Bio-One). Each well was measured in triplicate with five meander per 
well with a total measurement time of 10 sec/well. Scanning parameters were set to 50 Hz 
beam scanner, 100 mm scan path length and 2000 mm positioning table movement. Results 
were evaluated with a 2D-SIFT software module (Evotec-Technologies) 
2.8 Statistical analysis 
Data generated with the solid phase binding assay were represented with mean values and 
standard error of the mean (SEM). Statistical analysis was performed applying the Mann-
Whitney Test with the Sigma Plot 12.5 software. Significance is depicted with stars:  
*: p<0.05; **: p<0.01; ***: p<0.001. 
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3 Results 
As a central event in CADASIL, mutant Notch3-ECD accumulates at the surface of vascular 
smooth muscle cells (vSMCs) in the tunica media of vessel walls, which likely promotes the 
abnormal recruitment of functionally relevant ECM proteins (Monet-Lepretre et al., 2013). 
In this thesis, potential candidates introduced below were studied in order to identify 
aggregate constituents involved in mediating Notch3-ECD toxicity using post-mortem brain 
material from CADASIL patients and controls.  
3.1 Human post-mortem brain samples 
A total of six CADASIL brain samples (mean donor age: 64.3 years) were compared to six 
age- and sex-matched controls (mean donor age: 61.3 years) with no known 
cerebrovascular disorders (Table 12). Since CADASIL mainly affects the white matter, 
regions of the frontal sub-cortex (gyrus frontalis medius and frontal lobe) were used except 
for patient 6 (CAD 6), for whom only a sample from the frontal cortex was available. The 
analysis techniques used were limited by the amount and type (frozen or paraffin-
embedded) of the obtained material (Table 12).  
For all patients, genomic sequencing of NOTCH3 exons resulted in the detection of 
previously described Notch3 mutations genetically confirming the diagnosis CADASIL. All 
mutations led to the gain or loss of one or more cysteines within a single epidermal growth 
factor (EGF)-like repeat resulting in an odd number of this amino acid residue as observed 
for the vast majority of CADASIL mutations. The patient samples display a representative 
spectrum of characteristic mutations: the missense mutations C144S, R153C (both within 
EGF-like repeat 3) and R110C (within EGF-like repeat 2) are located in exon 4 (Joutel et al., 
1997, Dichgans et al., 2000) and exon 3 (Joutel et al., 1997), respectively. The more rare 
deletion D239_D253del (within EGF-like repeat 6) locates in exon 5 and causes the loss of 
15 amino acids including three cysteines (Cys240, Cys245 and Cys251) (Dichgans et al., 
2001). Whereas all these mutations are situated within the mutational hotspot in exons 2 
through 6 encompassing 86% of all CADASIL mutations (Peters et al., 2005a), the rare 
missense mutation C1261R resides in EGF-like repeat 32 close to the Notch3 
transmembrane domain (Joutel et al., 1997).   
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Table 12: Overview of post-mortem brain samples. CAD: CADASIL, Ctrl: Control.  
Description Sex Age Mutation Application 
CAD 1 M 64 R110C Histological stainings, Immunoblot 
CAD 2 F 66 D239_D253del Histological stainings, Immunoblot 
CAD 3 M 68 C144S Histological stainings, Immunoblot 
CAD 4 F 60 R153C Immunoblot 
CAD 5 F 70 C1261R Immunoblot 
CAD 6 F 58 R153C Immunoblot 
Ctrl 1 M 61 - Histological stainings, Immunoblot 
Ctrl 2 F 55 - Histological stainings, Immunoblot 
Ctrl 3 F 60 - Histological stainings, Immunoblot 
Ctrl 4 F 73 - Immunoblot 
Ctrl 5 M 60 - Immunoblot 
Ctrl 6 F 59 - Immunoblot 
 
3.2 Analysis of Notch3 aggregates by biochemical fractionation 
3.2.1 Notch3-ECD accumulates in CADASIL-affected brains 
In a first approach, sequential protein extraction from brain samples was performed to 
enrich Notch3-ECD and potential co-aggregating proteins (Figure 10). Efficient 
solubilization of mutant Notch3-ECD requires a combination of sodium dodecyl sulfate 
(SDS) and β-mercaptoethanol (β-ME) (Duering et al., 2011, Monet-Lepretre et al., 2013). 
Therefore, a modified version of a previously established extraction protocol using 
increasing solubility strength was applied, which allows the enrichment of Notch3-ECD 
deposits. The procedure is described in detail in figure 10 A and yielded three fractions 
(Tris, SDS, β-ME), which were subsequently analyzed by immunoblotting. Analysis of one 
CADASIL (CAD 1) and one control (Ctrl 1) sample using an anti-Notch3-ECD antibody 
revealed the presence of a ~210 kDa band in the β-ME fraction of patient, but not control 
material confirming the enrichment of disulfide-bridged Notch3-ECD in 
CADASIL-affected tissue by the sequential extraction procedure. β-tubulin served as a 
loading control since it exists in a soluble monomeric as well as polymerized form and is 
thus present in each fraction (Mandelkow and Mandelkow, 1992). 
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Figure 10: Sequential extraction of human brain samples. A) Schematic representation of the 
extraction procedure. Briefly, 30 mg of brain tissue was homogenized in 50 mM Tris pH 7.5, 
centrifuged and the resulting supernatant (Tris fraction) collected. After solubilization of the pellet 
in Tris buffer/1 % SDS and re-centrifugation, the SDS-soluble fraction was obtained. Detergent 
insoluble material was finally resuspended in Tris buffer/1 % SDS/5 % β-ME and clearance by 
centrifugation yielded the β-ME fraction. B) All three fractions obtained from an extraction of a 
CADASIL patient (CAD) and a control (Ctrl) sample were subjected to SDS-PAGE and 
immunoblotted with anti-Notch3-ECD 3G6 and anti-β-tubulin antibodies. Because of the 
impossibility of determine the protein concentrations in β-ME fractions, equal loading was ensured 
by adjusting protein amounts following Coomassie staining. Shown is a representative immunoblot 
from at least five independent extractions of three CADASIL and three control autopsies each.  
3.2.2 TSP-2 and LTBP-4 are enriched in CADASIL brain samples 
Having established this effective protein extraction procedure, potential Notch3-ECD 
aggregate constituents in the β-ME fraction were analyze expecting that co-aggregating 
proteins co-distribute in this fraction. Since Notch3-ECD deposits are extracellular 
structures located at the surface of vSMCs, the focus was set on ECM and matricellular 
(ECM-associated) proteins. This approach was supported by the recent results from a study 
by Monet-Lepretre et al., which reported the preferential enrichment of ECM constituents 
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in a proteomic analysis of a Notch3-ECD enriched fraction from CADASIL brain material 
(Monet-Lepretre et al., 2013).  
First, two matricellular proteins, thrombospondin-2 (TSP-2) and latent transforming 
growth factor-β (TGF-β) binding protein 4 (LTBP-4), were selected for analysis. TSP-2 has 
been shown to interact with the shedded Notch3-ECD to mediate its re-uptake into 
neighboring cells (Meng et al., 2009, Meng et al., 2010). Moreover, our group previously 
demonstrated that TSP-2 co-aggregates with CADASIL-relevant mutant Notch3 fragments 
in vitro providing experimental evidence for a pathological co-aggregation (Duering et al., 
2011). LTBP-4 was among the proteins identified in the study by Monet-Lepretre et al. as 
component of Notch3 aggregates isolated from a CADASIL mouse model. It is a member of 
the LTBP family, which regulates TGF-β signaling, a key pathway of the cerebral 
microvasculature involved in cell proliferation, differentiation, apoptosis and extracellular 
matrix production (Ruiz-Ortega et al., 2007).  
The two candidate proteins were analyzed by immunoblotting for their distribution in the 
Notch3-ECD-enriched β-ME fractions of CAD 1-2 and Ctrl 1-2, the four samples available 
in this early phase of the project. Analysis of TSP-2 yielded a strong immunoreactivity in 
patient but not control material (Figure 11 A). For LTBP-4, although present in controls, a 
clear increase in patient samples was observed (Figure 11 B). This demonstrated 
co-fractionation of both proteins with mutant Notch3-ECD indicating their association with 
Notch3-ECD deposits. However, due to a lack of appropriate antibodies, co-localization 
studies on paraffin-embedded or frozen tissue sections could not be performed (see below). 
Thus, definite proof for the role of TSP-2 and LTBP-4 in Notch3-ECD deposition could not 
be provided during this work.  
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Figure 11: TSP-2 and LTBP-4 co-fractionate with Notch3-ECD in the β-ME fraction of CADASIL 
brains. Brain samples were sequentially extracted and the β-ME fraction was immunoblotted with 
A) anti-TSP-2 and B) anti-LTBP-4 as well as anti-β-tubulin antibodies. Representative blots from at 
least three independent extractions of three CADASIL and three control subjects are shown. 
3.2.3 Isolation of brain vessels 
During the initial analyses, immunoblotting for α-smooth muscle actin (α-SMA), a vSMC 
marker protein present in the β-ME fraction indicative for the amount of vessel tissue in the 
different samples, was also performed. As depicted in Figure 12, large heterogeneities in 
α-SMA amounts were observed despite relatively homogenous β-tubulin intensities. 
Moreover, the strongest signal was observed in one of the patient samples (CAD 2), which 
is expected to contain reduced α-SMA levels due to the well-known loss of vSMCs in 
CADASIL-affected vessels (Okeda et al., 2002). This indicated varying amounts of vessels 
in each brain extract although tissue samples from similar brain regions were used for the 
sequential extractions. Since the aim was to study differences in vessel proteins, the 
presence of roughly comparable amounts of vessels in each extract was desirable.  
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Figure 12: Brain lysates show varying contents of vessel marker α-SMA. Human brain 
homogenates were sequentially extracted and the β-ME fraction was immunoblotted with anti-
α-SMA and anti-β-tubulin antibodies. Shown is a representative immunoblot from at least five 
independent extractions. α-SMA: smooth muscle actin.  
Therefore, a previously described method (Monet-Lepretre et al., 2013) to isolate vessels 
including intraparenchymal arteries and arterioles, veins and capillaries from brain 
samples was established. The main steps of the isolation procedure are described in Figure 
13A. It allows the removal of brain parenchymal tissue including myelin resulting in highly 
pure preparations of brain vessels as demonstrated by light microscopical analysis (Figure 
13 B).  
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Figure 13: Vessel isolation from brain samples. A) 50 mg of brain tissue was homogenized in a 
tissue grinder with a smooth pestle allowing vessels to stay intact. Subsequent density gradient 
centrifugation in 15 % Ficoll resulted in pelletizing of vessels and cell debris, while myelin was 
floating on top of the gradient. After discarding the supernatant, the pellet was transferred onto a 
40-µm nylon mesh, abundantly washed and purified vessels were collected by inversion of the 
mesh. B) Microscopic examination demonstrated the purity of the preparation.  
Isolated vessels were subjected to sequential fractionation as described in chapter 3.2.1. 
Western Blotting of the β-ME fractions from three patients and three controls for α-SMA 
demonstrated the sample homogeneity and the expected reduction of α-SMA expression in 
CADASIL-affected vessels could be observed in all patient samples (Figure 14 A). Analysis 
of Notch3-ECD expression in the β-ME fractions of all available samples demonstrated the 
enrichment of Notch3-ECD in all patient, but not control vessels (Figure 14 B). The low 
intensity of the band in the CAD 2 sample is due to the low total protein amounts loaded 
(compare tubulin signals), a consequence of the impossibility to determine the protein 
concentration in the β-ME fractions. A repetition of immunoblots with adjusted protein 
amounts was not always possible due to the scarceness of the available brain material. 
However, accumulation of Notch3-ECD in the CAD 2 sample had already been 
demonstrated using whole brain material. Thus, the presence of Notch3-ECD deposits 
could be confirmed in all patients.  
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Figure 14: Immunoblot analysis of β-ME fractions from purified brain vessels. A) Vessel isolation 
allows the precise study of vessel-related proteins. Purified brain vessels were sequentially extracted 
and the β-ME fraction immunoblotted with anti-α-SMA and anti-β-tubulin antibodies. B) Notch3-
ECD is specifically enriched in the β-ME fraction of purified patient vessels. Shown is an 
immunoblot of the β-ME fraction with anti-Notch3-ECD 3G6 and anti-β-tubulin antibodies with all 
available samples. 
To validate the specificity of the sequential extraction method, amyloid precursor protein 
(APP) was analyzed, which plays no known role in CADASIL (Paquet et al., 2010) and, like 
Notch3, represents a type I transmembrane receptor with a large extracellular domain that 
undergoes the same proteolytic cleavages. Immunoblotting of the β-ME fractions revealed 
the presence of APP in both patient and control samples, albeit at varying levels with no 
disease-related trend (Figure 15). Based on this finding, an artificial enrichment of plasma 
membrane proteins by the sequential extraction method is unlikely. It was therefore 
concluded that the vessel isolation method is suited to identify new potential Notch3-ECD 
aggregate constituents. 
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Figure 15: APP displays no CADASIL-related differences in the β-ME fraction of purified vessels. 
Purified brain vessels were sequentially extracted. Shown is an immunoblot of the β-ME fraction 
with anti-APP and anti-β-tubulin antibodies. APP: amyloid precursor protein. 
3.2.4 Fibronectin and LTBP-1 co-fractionate with Notch3-ECD in 
CADASIL-affected vessels 
Since the role of the initially identified factors TSP-2 and LTBP-4 in Notch-ECD deposition 
could not be further investigated due to the lack of appropriate antibodies (see 3.2.2), 
alternative candidates were explored. Among the four members of the LTBP family of 
TGF-β signaling regulators, LTBP-1 has by far been studied most extensively and shown to 
bind to all three TGF-β isoforms (TGF-β1, TGF-β2, TGF-β1) with similar efficiency 
(Saharinen and Keski-Oja, 2000). It mediates TGF-β sequestration by interacting with 
fibronectin and fibrillin-1, key structural components of blood vessel ECM, which had also 
been identified in the proteomic study on CADASIL brains (Monet-Lepretre et al., 2013). 
Moreover, fibrillin-1 and LTBP proteins, like Notch3, contain cysteine-rich domains 
including EGF-like repeats, which could possibly be involved in pathological disulfide 
bond-mediated aggregation processes. Based on these considerations, LTBP-1, fibronectin 
and fibrillin-1 were selected for further investigation. 
For immunoblotting experiments the β-ME fractions of purified vessels from four patients 
and four controls were used. Staining for fibrillin-1 with various antibodies did show 
conclusive results neither in control nor in patient samples (data not shown). In contrast, 
fibronectin and LTBP-1 were clearly seen in patient, but almost absent in control material. 
Staining intensities within patient samples varied considerably, with the most prominent 
signals in CAD 4 and 5. A similar pattern had already been observed for Notch3 (see 
Figure 14). Thus, both fibronectin and LTBP-1 are strongly enriched in CADASIL-affected 
brain vessels and the extent of their accumulation within individual samples parallels that 
of Notch3-ECD. This clearly demonstrated co-fractionation with Notch3-ECD indicating a 
role in Notch3-ECD deposition. 
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Figure 16: Fibronectin and LTBP-1 are increased in the β-ME fraction of CADASIL vessels. 
Purified vessels were sequentially extracted and the β-ME fraction was immunoblotted with anti-
fibronectin, anti-LTBP-1 and anti-β-tubulin antibodies. A representative blot from two independent 
extractions of six CADASIL and control subjects is shown.  
3.3 Co-localization analysis in human brain sections  
Biochemical co-fractionation might occur independently of Notch3-ECD aggregates, 
especially with ECM proteins exhibiting poor solubility. Thus, additional evidence for a 
possible connection of the examined proteins with mutant Notch3-ECD was required. 
Therefore, immunohistochemical studies on human brain sections from CAD 1-3 and Ctrl 
1-3 were performed to study their spatial distribution with respect to Notch3-ECD 
deposits. The latter can be visualized nicely by immunohistochemical staining of paraffin-
embedded as well as frozen tissue (Joutel et al., 2000).  
To confirm the presence of Notch3 deposits in the CADASIL patients, paraffin-embedded 
tissue was stained with a monoclonal anti-Notch3-ECD antibody. While Notch3-ECD 
could not be detected in control sections, it displayed elevated immunoreactivity in the 
tunica media of patient arterioles (Figure 17). Since Notch3 is exclusively expressed in 
vSMCs and pericytes of the tunica media, the extracellular deposits are located at the 
surface of these cells marking the tunica media and allowing a rough distinction of the 
three vessel layers (Joutel et al., 2000). In addition to Notch3-ECD deposits, the 
characteristic pathologic thickening of the tunica intima and tunica adventitia was 
observed (Figure 17 upper panels). 
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Figure 17: Notch3-ECD deposits are located in the tunica media in CADASIL arterioles. Paraffin-
embedded brain sections were stained with the anti-Notch3-ECD 2G8 antibody and visualized with 
AEC (reddish brown). Nuclei were counterstained with hematoxylin (blue). The images are 
representatives of two independent experiments. 
Immunofluorescence analysis allows an even more precise visualization of individual 
Notch3-ECD aggregates (Joutel et al., 2000) and co-localization analyses with additional 
proteins. Frozen tissue sections of CAD 1 and Ctrl 1 were co-stained for Notch3-ECD and 
collagen type IV, a basement membrane marker used to visualize vessels. As observed on 
paraffin sections, Notch3-ECD was not detectable in control tissue due to low expression. 
However, the focal enrichment of Notch3-ECD immunoreactivity indicative of deposits 
was observed in CADASIL arterioles (Figure 18 A) and, even more pronounced, in small 
capillaries (Figure 18 B) 
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Figure 18: Notch3-ECD is observed as granular deposits in CADASIL vessels. Frozen brain 
sections of a patient (CAD 1) and a control (Ctrl 1) were stained with the anti-Notch3-ECD 2G8 and 
anti-collagen type IV antibody, a basement membrane marker, and analyzed by 
immunofluorescence. Images are representatives for least five different experiments with three 
CADASIL and control samples each. Pictures showing arterioles (A) and small capillaries (B) were 
taken with an inverse fluorescence and confocal microscope, respectively.   
3.3.1 Fibronectin and fibrillin-1 accumulate in CADASIL vessels 
independently of Notch3-ECD deposits  
To study the localization of fibronectin, paraffin-embedded brain sections were stained 
with an anti-fibronectin antibody. In control vessels, fibronectin was detected in moderate 
amounts as a fine lining of the tunica intima and adventitia (Figure 19), where it is 
abundantly expressed (Wagenseil and Mecham, 2009). In contrast, a dramatic increase was 
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observed in the thickened tunica adventitia of CADASIL vessels in agreement with the 
increased fibronectin levels observed in immunoblot experiments (see Figure 16). 
However, the staining pattern clearly differed from that of Notch3-ECD (Figure 19 right 
panel) arguing against a co-localization with Notch3-ECD aggregates. 
 
Figure 19: Fibronectin is increased in the tunica adventitia and intima of CADASIL patients 
while Notch3-ECD is located in the tunica media. Paraffin brain sections were stained with anti-
fibronectin or anti-Notch3 2G8 antibodies and visualized with AEC (reddish brown). Cell nuclei 
were counterstained with hematoxylin (blue). Shown are representative images of three 
experiments.  
In contrast to immunoblot analysis, the fibrillin-1 antibody worked excellently in 
immunohistochemical analyses. It revealed weak immunoreactivity in control vessels of 
paraffin-embedded tissue sections showing a fibrillar structure within the tunica adventitia 
(Figure 20). In CADASIL patients, a markedly elevated signal intensity was observed 
resulting in the continuous labeling of a thin layer at the perimeter of the tunica adventitia 
(Figure 20). This finding was confirmed by immunofluorescence stainings on frozen tissue 
sections, where the signal for fibrillin-1 showed a fibrous pattern, which was strongly 
increased in CADASIL vessels. Additionally, fibrillin-1 is also detected at the tunica intima 
with a lower intensity (Figure 20), since fibrillin-1 microfibrils are also found at the tunica 
elastica interna (Wagenseil and Mecham, 2009).   
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Figure 20: Fibrillin-1 is increased in the tunica adventitia of CADASIL patients. Paraffin-
embedded brain sections were stained with an anti-fibrillin-1 antibody and visualized with AEC 
(reddish brown). Cell nuclei were counterstained with hematoxylin (blue). Frozen brain sections 
were stained with the anti-fibrillin-1 antibody and analyzed by immunofluorescence. Shown are 
representative images of two experiments with three CADASIL and three control samples.  
For fibrillin-1, a co-localization could be studied more directly by performing co-staining 
with Notch3-ECD on frozen sections of CADASIL patients (for fibronectin this was not 
possible due to the lack of an appropriate antibody). The fibrous pattern for fibrillin-1 is 
clearly distinct from the granular Notch3-ECD immunoreactivity confirming the lack of 
spatial overlap between both proteins (Figure 21). 
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Figure 21: Fibrillin-1 does not co-localize with Notch3-ECD. Frozen brain sections were stained 
with the anti-fibrillin-1 and anti-Notch3-ECD 2G8 antibodies and analyzed by immunofluorescence. 
Shown are representative images from three experiments.  
In summary, these findings suggested that the accumulation of fibrillin-1 and fibronectin in 
CADASIL vessels occurs independently of Notch3-ECD likely representing a fibrotic 
process secondary to deposit formation. Therefore, both proteins were excluded as direct 
participants in Notch3-ECD deposition.  
3.3.2 LTBP-1 is recruited to Notch3-ECD deposits 
To study the localization of the third candidate protein, LTBP-1, in CADASIL vessels, only 
immunoflouresence stainings on frozen tissue sections could be performed due to the lack 
of a suitable antibody for paraffin–embedded material. In control brain sections, arterioles 
(Figure 22 A) as well as capillaries (Figure 22 B), visualized by collagen type IV staining, 
showed a weak immunoreactivity for LTBP-1. In contrast, LTBP-1 levels were markedly 
increased in sections of CAD 1 recapitulating the enrichment observed in β-ME fractions 
after biochemical fractionation (see Figure 16). Most importantly, LTBP-1 in CADASIL 
vessels appeared not uniform but restricted to focal granules reminiscent of Notch3-ECD 
deposits, as most clearly seen in capillaries (Figure 22 B).  
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Figure 22: LTBP-1 shows a focal enrichment in CADASIL vessels. A-B) Frozen brain sections were 
stained with anti-LTBP-1 and anti-collagen type IV antibodies and analyzed by 
immunofluorescence. Shown are representative images from at least four experiments taken with A) 
an inverse microscope and B) a confocal microscope.  
Therefore, co-stainings were performed and analyzed by confocal microscopy. Indeed, 
LTBP-1 and Notch3-ECD yielded almost completely overlapping signals in all examined 
patients (Figure 23) demonstrating co-localization. This result strongly suggested specific 
LTBP-1 sequestration within Notch3-ECD aggregates. The occurrence of this finding in 
three independent patients carrying different NOTCH3 mutations argued for its specificity. 
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Figure 23: LTBP-1 co-localizes with Notch3-ECD aggregates. Frozen brain sections were stained 
with anti-LTBP-1 and anti-Notch3-ECD 2G8 antibodies and analyzed by immunofluorescence. 
Shown are representative images from at least four experiments with three CADASIL and three 
control brains taken with a confocal microscope. 
LTBP-1 represents a key mediator of the pro-fibrotic cytokine TGF-β, a well known 
regulator of microvasculature function (Doyle et al., 2012), and its recruitment into 
Notch3-ECD deposits implicates a potential involvement of the TGF-β pathway in 
CADASIL. Notably, dysregulation of TGF-β signaling has been demonstrated in a number 
of inherited vascular diseases (ten Dijke and Arthur, 2007) including cerebral autosomal 
recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), a 
recessive hereditary SVD with a CADASIL-like pathology (Hara et al., 2009,). Moreover, 
TGF-β signaling has been suggested as an important contributor to vascular remodeling in 
sporadic SVD (Thompson and Hakim, 2009). Therefore, signs of altered TGF-β activity in 
the brain samples were investigated.  
3.3.3 LAP accumulates in the tunica media of CADASIL vessels 
The TGF-β pro-protein is processed in the cell into two fragments, the mature TGF-β, a 
dimer linked by disulfide bridges, and its pro-domain, the latency-associated peptide 
(LAP) (Dubois et al., 1995) (Figure 24). LAP keeps TGF-β in an inactive state (Shi et al., 
2011) and mediates the interaction with LTBP proteins, which upon secretion of this 
complex promote its attachment to the ECM via interactions with fibronectin and fibrillins. 
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The mature TGF-β ligand can be released from the ECM by a variety of mechanisms 
(Olofsson et al., 1995, Isogai et al., 2003).  
 
Figure 24: Schematic representation of latent TGF-β synthesis and secretion. See text for details.  
LAP and mature TGF-β are non-covalently attached, while LTBP-1 and LAP are cross-linked via a 
disulfide-bridge. Orange/blue bar: pre-pro TGF-β; blue dimer: LAP (latency associated peptide); 
orange dimer: mature TGF-β (transforming growth factor-β); green hemicycle: LTBP-1 (latent TGF-β 
binding protein-1); grey waved lines: fibronectin; grey bar: fibrillin-1.  
Therefore, expression levels and localization of LAP were studied in the brain samples. 
First, protein levels were analyzed by immunoblotting of the β-ME fractions from purified 
vessels of CAD 2-5 and shown to be increased in all four CADASIL patients examined 
suggesting a specific enrichment (Figure 25 A). Next, immunohistochemical studies on 
paraffin-embedded tissue of CAD 1-3 and Ctrl 1-3 were performed to study the localization 
of LAP. While in controls expression could not be observed, LAP was strongly increased in 
CADASIL vessels (Figure 25 B). Most importantly, the immunoreactivity was restricted to 
the tunica media, the vessel layer containing Notch3-ECD aggregates. Due to the 
ineptitude of the anti-LAP antibody, immunofluorescence staining could not be performed 
preventing co-localization studies. Nevertheless, these findings suggest an LTBP-1-
mediated enrichment and sequestration of immature TGF-β within Notch3-ECD 
aggregates. It remains to be determined whether this finding has implications on TGF-β 
signaling in CADASIL pathogenesis. 
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Figure 25: LAP is increased in CADASIL brain vessels. A) The β-ME fraction of sequentially 
extracted purified brain vessels were immunoblotted with anti-LAP and anti-β-tubulin antibodies. 
Shown is a representative image of two independent experiments. B) Paraffin-embedded brain 
sections were stained with the anti-LAP antibody and visualized with AEC (reddish brown). Nuclei 
were counterstained with hematoxylin (blue). Shown are representative images of two experiments. 
3.4 LTBP-1 directly interacts with Notch3 in vitro 
From the studies on brain samples LTBP-1 emerged as highly promising candidate for a 
role in Notch3-ECD aggregation. To investigate this more directly, in vitro approaches were 
employed. Since recruitment of ECM proteins into Notch3-ECD deposits might be 
facilitated by direct protein-protein interactions (Monet-Lepretre et al., 2013), the binding 
of LTBP-1 to Notch3-ECD was investigated by applying a solid-phase binding assay, an 
approach successfully used in the past to analyze interaction partners of both proteins 
(Meng et al., 2009, Massam-Wu et al., 2010). Since correctly folded full-length Notch3-ECD 
cannot be purified (Duering et al., 2011), a recombinantly generated Notch3 fragment 
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harboring the first 11 EGF-like repeats was chosen (N3EGF1-11-Fc). For efficient expression 
and purification this fragment contained a carboxy-terminally IgG-Fc affinity tag. As a 
soluble ligand, LTBP-1 conditioned medium derived from transiently transfected HEK293T 
cells was used. There are two LTBP-1 isoforms, LTBP-1L (long) and LTBP-1S (short), 
generated by the alternative use of two separate promoters within the same gene (Koski et 
al., 1999). Whereas LTBP-1L is mainly expressed during development, LTBP-1S is the major 
isotype in adult life and was thus selected for this study (in the following termed LTBP-1) 
(Todorovic and Rifkin, 2012).  
To perform this assay, N3EGF1-11-Fc or the control ligand IgG-Fc were immobilized to 
microtiter plate wells and LTBP-1 conditioned medium was added. Subsequently, 
antibody-mediated labeling of bound LTBP-1 allowed quantification by a colorimetric 
detection procedure. An almost fivefold and highly significant increase in LTBP-1 binding 
to N3EGF1-11-Fc compared to the control was observed (Figure 26 A).  
To verify the binding of LTBP-1 to immobilized N3EGF1-11-Fc by immunoblotting, the 
bound proteins were recovered from microtiter plates after assay completion. Equally 
efficient immobilization of N3EGF1-11-Fc and IgG-Fc was demonstrated by comparing the 
blotting signals of recovered proteins with that of a defined amount of purified protein 
(Figure 26 B). Immunoblotting for LTBP-1 in the recovered samples revealed its presence 
only in the N3EGF1-11-Fc, but not IgG-Fc lane confirming the specificity of the binding. 
LTBP-1 appeared as a high-molecular-weight band, which most likely represents 
oligomeric LTBP-1 not dissolved under the solubilization conditions used (Figure 26 C). 
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Figure 26: LTBP-1 binds to immobilized Notch3. A) Binding of full-length LTBP-1 derived from 
HEK293T cell conditioned medium to immobilized Notch3 (N3EGF1-11-Fc) or control ligand 
(IgG-Fc) was measured by immunodetection using an anti-LTBP-1 antibody. Upon incubation with 
a peroxidase-coupled secondary antibody, the substrate was added allowing a colorimetric 
measurement. Background absorbance of conditioned media from mock-transfected HEK293T cells 
was subtracted and relative amounts of bound LTBP-1 are shown. Binding of LTBP-1 to the control 
was set to 1 and results are expressed as mean +SEM of 7 independent experiments. *** p<0.001; 
Mann-Whitney Test. B-C) Bound proteins were recovered from wells by the addition of Lämmli 
buffer after assay completion. B) Immobilized proteins bind comparably to well plates. 100 ng pure 
protein and recovered N3EGF1-11-Fc (top panel) or IgG-Fc (lower panel) were immunodetected 
using an anti-human-IgG antibody. C) Bound LTBP-1 was evaluated by immunoblotting with an 
anti-LTBP-1 antibody and predominantly detected in oligomeric form. Shown are representative 
blots from at least three independent experiments.  
To demonstrate the relevance of the solid phase binding assay, fibronectin was chosen as a 
control immobilizing partner, since its interaction with LTBP-1 is well established (Dallas et 
al., 2005). Fibronectin was immobilized with similar efficiency to microtiter plate wells as 
demonstrated by Western Blotting (Figure 27 A). Quantitation of the binding revealed a 
3.5-fold increase in LTBP-1 binding to fibronectin (Figure 27 B), indicating that the assay 
adequately reflects in vivo conditions.  
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Figure 27: LTBP-1 binds to the known interactor fibronectin with a similar affinity than to 
Notch3. A) Bound fibronectin was recovered from microtiter well plates after assay completion by 
the addition of Lämmli buffer and compared to 100 ng pure protein. Shown is a representative 
immunoblot of two independent experiments detected with an anti-fibronectin antibody. B) Binding 
of LTBP-1 conditioned media to immobilized fibronectin or plastic was colorimetrically measured 
using the anti-LTBP-1 antibody for detection. Results are expressed as mean +SEM of 7 independent 
experiments. *** p<0.001; Mann-Whitney Test. 
To map the Notch3 binding domain within LTBP-1, two truncated and epitope-tagged 
LTBP-1 expression constructs were generated. They either lack the N-terminus with the 
fibronectin interaction domain (LTBP-1ΔN) or the C-terminus containing the LAP and 
fibrillin-1 binding site (LTBP-1ΔC_V5) (Figure 28 A). LTBP-1ΔN was generated in two 
versions: HA-tagged LTBP-1ΔN_HA, which was used in assays with cell supernatants and 
V5-His-tagged LTBP-1ΔN_V5 for assays requiring purified LTBP-1. Immunoblotting with 
an anti-V5 antibody revealed molecular masses of ~220 kDa, ~120 kDa and ~140 kDa for 
LTBP-1, LTBP-1ΔC_V5 and LTBP-1ΔN_V5, respectively (Figure 28 B). 
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Figure 28: LTBP-1 deletion constructs. A) Schematic representation of the used LTBP-1 constructs 
and their domain organization including cysteine rich repeats (orange circles), a hybrid domain 
(grey circle), EGF-like repeats (blue squares) and V5-His or hemagglutinin (HA) tags (open circles). 
The fibronectin, LAP/TGF-β and fibrillin-1 binding regions are indicated. Note that LTBP-ΔC-HA 
was used in assays with cell supernatants and LTBP-ΔC-V5 in assays requiring purified LTBP-1. 
Adapted from Todorovic and Rifkin, 2012. B) Immunoblotting of LTBP-1, LTBP-1ΔC_V5 and LTBP-
1ΔN_V5 from HEK293T cell-derived conditioned media with an anti-V5 antibody.  
To assess the binding capacities of these LTBP-1 deletion fragments, they were transiently 
transfected into HEK293T cells and conditioned media were used in the binding assay. 
While the loss of the LTBP-1 N-terminus completely abrogated binding, LTBP-ΔC_V5 
retained the ability to bind N3EGF1-11-Fc (Figure 29). To exclude an indirect interaction 
mediated by other factors present in the conditioned media, LTBP-1ΔC_V5 was purified 
using an affinity chromatography approach (see 3.5). Indeed, the binding of purified 
LTBP-1ΔC_V5 was as efficient as the corresponding conditioned medium (Figure 29) 
demonstrating that the interaction is direct. 
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Figure 29: LTBP-1 binding to Notch3 is mediated by its N-terminus. Binding of conditioned media 
from HEK293T cells transfected with LTBP-1ΔN_HA and LTBP-1ΔC_V5 or purified LTBP-1ΔC_V5 
to immobilized N3EGF1-11-Fc or IgG-Fc was immunodetected using anti-LTBP-1 (LTBP-1ΔN_HA) 
or anti-V5 (LTBP-1ΔC_V5) antibodies respectively. Background absorbance of conditioned media 
from mock-transfected HEK293T cells or PBS was subtracted. Relative amounts of bound LTBP-1 
are shown. Results are expressed as mean + SEM of five (LTBP-1ΔC_V5) and four (LTBP-1ΔN_HA) 
independent experiments. n.s.: not significant, *** p<0.001; ** p<0.01; Mann-Whitney Test.  
In summary, the data suggest that the sequestration of LTBP-1 into Notch3-ECD deposits is 
mediated by a direct interaction involving a region within the first 11 EGF-like repeats of 
the Notch3-ECD and the amino-terminal 1-689 aa of LTBP-1.  
3.5 LTBP-1ΔC co-aggregates with mutant Notch3 
To provide proof for a direct participation of LTBP-1 in the Notch3-ECD aggregation 
process, a previously established in vitro assay recapitulating the multimerization of 
mutant Notch3 was used (Opherk et al., 2009a, Duering et al., 2011). This assay is based on 
scanning for intensely fluorescent targets (SIFT), a unique technique, which distinguishes 
single protein particles from aggregated multimers in a confocal setup permitting the 
quantification of de novo protein aggregation in solution (Giese et al., 2005). Purified 
proteins are labeled with different fluorescent dyes (red or green) and pairwise incubated 
to allow the formation of multimeric particles. Dye intensities reflecting particle 
composition and size are measured via a light detector following dual-laser excitation and 
results are plotted in a two-dimensional graph. As depicted in Figure 31 A, monomers and 
low-molecular-weight oligomers appear as low-intensity signals in the lower left corner of 
the plot, whereas homomeric and heteromeric multimers are represented as mono-colored 
or dual-colored high-intensity signals, respectively. 
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For analyses, the previously described wild-type and R183C mutant-carrying Notch3 
fragments encompassing EGF-like repeats 1-5 (N3EGF1-5) (Duering et al., 2011) as well as 
the LTBP-1 deletion variants LTBP-1ΔN and LTBP-1ΔC were used. The Notch3 EGF1-5 
fragment harbors the mutational hotspot region (Peters et al., 2005a) and is efficiently 
secreted by HEK293E cells and thus correctly folded (larger Notch3-ECD fragments are 
incompletely folded and invariably retained within cells) (Duering et al., 2011). Purified 
red- and green-labeled Notch3 fragments were provided by Patrizia Hanecker (Institute for 
Stroke and Dementia Research, Munich) who also assisted in performing the following 
experiments. 
For the purification of LTBP-1 deletion variants, conditioned medium from HEK293E cells 
transiently transfected with LTBP-1ΔC_V5 or LTBP-1ΔN_V5 was dialyzed and 
subsequently affinity-purified using their C-terminal V5-His tag. Silver staining of eluted 
fractions demonstrated sufficient purity of both fragments with LTBP-1ΔC_V5 showing a 
slightly better quality (Figure 30). For fluorescent labeling, elution fraction 4 of 
LTBP-1ΔC_V5 and combined fractions 4 and 5 of LTBP-1ΔN_V5 were used. To assess their 
co-aggregation potential, they were incubated in combination with wild-type or mutant 
N3EGF1-5 fragment for 1, 3 and 5/6 days to allow aggregation and subsequently analyzed 
by SIFT. Representative data of a day 1 experiment are depicted in Figure 31 B. 
 
Figure 30: Silver Staining of purified LTBP-1 fragments. Conditioned media from transiently 
transfected HEK293E cells with LTBP-1ΔC_V5 or LTBP-1ΔN_V5 were dialyzed and proteins were 
purified via their His-Tag using the Talon System. Eluted fractions 2-8 were separated by 
SDS-PAGE and visualized by silver staining. Three different batches of LTBP-1ΔC_V5 and one for 
LTBP-1ΔN_V5 were prepared.  
In line with our published data (Duering et al., 2011), N3EGF1-5 R183C formed higher-
order dual-color multimers, while the corresponding wild-type fragment did not show this 
tendency (Figure 31 B, C). When LTBP-1ΔC or LTBP-1ΔN were analyzed in combination 
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with N3EGF1-5 wild-type, no formation of dual-colored aggregates was observed. 
However, single-color LTBP-1 multimers were detected indicating self-aggregation, a 
finding already observed in the solid-phase binding assay (see Figure 26 C). Similarly, 
predominantly mono-colored multimers were formed when LTBP-1ΔN_V5 was combined 
with mutant N3EGF1-5 (Figure 31 B). In contrast, the combination of LTBP-1ΔC and 
mutant N3EGF1-5 yielded higher-order dual-color multimers with a distribution typical 
for mutant Notch3EGF1-5 fragments suggesting the generation of aggregates containing 
both proteins (Figure 31 B).  
 
Figure 31: LTBP-1ΔC specifically co-aggregates with mutant Notch3. A) Schematic representation 
of SIFT data evaluation with a 2-D histogram. Shown are particle brightnesses for each fluorophore 
on the individual axis (x-axis in green; y-axis in red) in 0-250 photons/bin in dots (a bin is the sum of 
photons that are detected in a timeframe). Adapted from Duering et al., 2011. B) Purified proteins 
were fluorescently labeled and incubated 24 h at 550rpm and 37 °C. SIFT analysis was performed in 
order to analyze the aggregational behavior of different combinations. Shown are representative 
images of 2-5 experiments with two separately purified and labeled LTBP-1ΔC_V5 batches and one 
batch of LTBP-1ΔN_V5. WT: Wild-type. 
In summary, it was concluded that LTBP-1 can multimerize with mutant Notch3, a process 
dependent on the presence of the interaction domain. These results further support the 
hypothesis that a direct interaction promotes co-aggregation. In combination with the 
findings on brain samples, they strongly suggest that LTBP-1 represents a component of 
Notch3-ECD deposits with a key role in CADASIL-relevant aggregation processes.  
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4 Discussion 
The extracellular accumulation and deposition of excess Notch3-ECD in small brain vessels 
penetrating the white and deep gray matter is an early manifestation and hallmark of 
CADASIL (Mayer et al., 1999). This process is considered the starting point of a chain of 
pathological events involving the recruitment and sequestration of functionally important 
ECM and ECM-associated (matricellular) proteins and eventually resulting in brain vessel 
dysfunction (Joutel, 2011). Using a candidate-based approach several ECM components 
with potential disease-specific roles were investigated using CADASIL patient and control 
brain samples. Five proteins were selected for analysis based on their role in ECM function. 
4.1 Thrombospondin-2  
Thrombospondin-2 (TSP-2) is an adhesive glycoprotein involved in ECM assembly and 
cell-to-matrix interactions (Calabro et al., 2014). It was selected for analysis since several 
previous studies had suggested a role in Notch3 biology (Meng et al., 2009, Meng et al., 
2010). TSP-2 binds directly to Notch3-ECD and potentiates Notch3/Jagged1 signaling 
(Meng et al., 2009). Moreover, it associates with low density lipoprotein receptor-related 
protein-1 stimulating Notch3-ECD endocytosis and clearance from the extracellular space 
(Meng et al., 2010). Most importantly with respect to CADASIL, our group previously 
demonstrated co-aggregation of TSP-2 with mutant Notch3 fragments in an in vitro 
aggregation assay (Duering et al., 2011). In the present study, an enrichment of TSP-2 in the 
β-ME fraction upon sequential extraction was observed indicating co-fractionation with 
Notch3 deposits. However, due to the lack of an appropriate antibody, 
immunohistochemical analyses in order to proof a spatial overlap could not be performed. 
Assumingly, co-aggregation of mutant Notch3-ECD and TSP-2 prevents the TSP-2-
mediated recycling of Notch3. The impaired clearance from the extracellular space in turn 
could promote the aggregation process resulting in a build-up of extracellular deposits 
over time. However, further studies are required to elucidate the precise role of TSP-2 in 
CADASIL development. 
4.2 Fibronectin and fibrillin-1 
Fibronectin and fibrillin-1 are major structural ECM components. While fibronectin is a 
dimeric protein interacting with other ECM components allowing the formation of an 
interconnected network and stable matrix, fibrillin-1 polymerizes into microfibrils to form 
a microfibrillar network (Raines, 2000). They are synthesized by vSMCs and fibroblasts and 
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mediate the interaction of vSMCs with the ECM influencing their adhesion, migration and 
survival in the arterial wall. Alterations in their functionality are known to have deleterious 
effects on ECM homeostasis (Judge and Dietz, 2005, White and Muro, 2011). Accumulation 
of fibronectin has previously been reported in a single CADASIL case (Oide et al., 2008). In 
the present thesis, this finding is now confirmed and extended and the abnormal 
enrichment of fibronectin as well as fibrillin-1 in brain vessels of three independent 
patients carrying different Notch3 mutations was demonstrated. However, the 
accumulation is observed within the tunica adventitia and intima, but not in the tunica 
media where Notch3-ECD aggregates are located. Immunofluorescent co-staining of 
fibrillin-1 and Notch3 clearly showed the difference in localization. This finding is 
interpreted as an indication against a direct involvement of fibronectin and fibrillin-1 in 
Notch3-ECD aggregation. It rather implies excess ECM production, which is known to 
occur during fibrosis, a pathological process also observed in CADASIL pathogenesis. 
Therefore, fibronectin and fibrillin-1 accumulation is considered as an event occurring 
secondary to Notch3-ECD deposition. A similar enrichment has been reported for various 
types of collagens (type I, III and VI) in the massively thickened tunica adventitia of 
CADASIL patients (Miao et al., 2004, Miao et al., 2006, Dong et al., 2012). Moreover, in the 
proteomic study by Monet-Lepretre et al., a number of additional matricellular proteins 
such as nidogen-1, laminin and perlecan were identified, which might accumulate due to 
arterial wall thickening (Monet-Lepretre et al., 2013). 
The excessive production, deposition and contraction of ECM are distinctive features of 
fibrotic diseases and usually advance over many months and years (Leask and Abraham, 
2004). Fibrosis occurs in a variety of vascular conditions including hereditary hemorrhagic 
telangiectasia, Marfan and Loeys-Dietz Syndrome and pulmonary arterial hypertension 
(ten Dijke and Arthur, 2007). The common denominator of all these vascular disorders is a 
dysregulation of transforming growth factor-β (TGF-β) signaling contributing to vessel wall 
malformations (Goumans et al., 2009). It was therefore decided to continue the candidate 
analysis by selecting extracellular factors involved in the TGF-β pathway. 
4.3 Latent TGF-β-binding proteins 
TGF-β, a well-described regulator of blood vessel formation and homeostasis, is secreted 
from cells as inactive complex and stored in the ECM. This complex, also termed large 
latency complex (LLC), consists of mature TGF-β, latency-associated peptide (LAP) and a 
member of the latent TGF-β binding protein (LTBP) family (Pardali and Ten Dijke, 2012). 
LAP keeps the mature ligand in a biologically inactive state and covalently links it to 
LTBP-1, -3 or -4 by a disulfide bond (Ramirez et al., 2007, Shi et al., 2011). Sequestration 
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within the ECM is mediated by interactions between LTBPs, fibronectin and fibrillin-1 
generating a reservoir of inactive TGF-β.  
Using mass spectrometry, Monet-Lepretre and colleagues identified LTBP-2 and LTBP-4 in 
human and murine Notch3-ECD enriched preparations, respectively (Monet-Lepretre et 
al., 2013). Thus, LTBPs as regulators of TGF-β bioavailability represent promising 
candidate molecules for a role in CADASIL pathogenesis. Since LTBP-2 does not bind 
TGF-β, the focus was set on LTBP-4 and LTBP-1, the latter being the best studied family 
member, binding equally efficient to all three TGF-β ligands (TGF-β1, TGF-β2, TGF-β1) 
(Saharinen and Keski-Oja, 2000). For both LTBPs, Western Blotting demonstrates a specific 
enrichment and co-fractionation with Notch3-ECD deposits in CADASIL samples. For 
LTBP-4, however, immunohistological analysis data could not be interpreted due to 
unclear antibody specificity and thus, a final conclusion about its role in Notch3-ECD 
aggregation could not be drawn. In contrast, LTBP-1 displayed an accumulation as well as 
a striking co-localization with Notch3-ECD deposits in CADASIL-affected vessels. The 
presence of this observation in three unrelated patients carrying different NOTCH3 
mutations argued for its specificity and suggested a role for LTBP-1 in Notch3 deposit 
formation.  
This finding prompted us to investigate the relationship between LTBP-1 and Notch3 in 
more detail. Monet-Lepretre and collegues proposed that a direct interaction is required for 
the recruitment of matricellular proteins into Notch3-ECD aggregates. Particularly, they 
established tissue inhibitor of metalloproteinase 3 (TIMP3) as a Notch3-ECD interactor and 
aggregate constituent, which is not affected by CADASIL mutations (Monet-Lepretre et al., 
2013). Therefore, a possible interaction between Notch3 and LTBP-1 was investigated using 
a solid-phase binding assay, an approach previously used to identify binding partners of 
both factors (Meng et al., 2009, Massam-Wu et al., 2010). Indeed, an interaction between the 
LTBP-1 N-terminal domain and the first 11 EGF-like repeats of Notch3-ECD was 
discovered. Since a purified mutant Notch3-ECD EGF1-11 fragment was not available and 
the mutant EGF1-5 fragments used in the co-aggregation assay (see below) could not be 
used as ligands due to their low stickiness, the effect of CADASIL mutations on the 
interaction could not be investigated. However, the data from Monet-Lepretre et al. and the 
present results from a co-aggregation assay (see below) suggest that LTBP-1 binding is 
preserved in Notch3 mutants. 
To provide proof for a direct participation of LTBP-1 in the Notch3-ECD aggregation 
process, a previously established in vitro assay based on scanning for intensely fluorescent 
targets (SIFT) was applied, which allows the quantitative monitoring of de novo aggregation 
of mutant Notch3 in solution (Opherk et al., 2009a, Duering et al., 2011). It so far represents 
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the only assay in which Notch3 aggregation can be analyzed under controlled conditions 
and it has been successfully used to demonstrate the disulfide dependency of mutant 
Notch3-ECD multimerization. Proteins used in this assay need to be purified in a correctly 
folded form and are therefore obtained from conditioned supernatants of transfected 
cultured cells. Since longer Notch3-ECD fragments are poorly secreted, a shorter Notch3 
fragment containing EGF-like repeats 1-5, the mutational hotspot region of CADASIL, are 
analyzed. As mentioned above, co-aggregation of TSP-2 with mutant Notch3 was 
demonstrated in this assay providing the first experimental evidence for a pathological 
co-aggregation mechanism (Duering et al., 2011). The present thesis demonstrated that 
while the LTBP-1 deletion variant containing the Notch3 binding site showed strong 
co-aggregation with the archetypal Notch3 mutant R183C, this tendency was not observed 
with the variant lacking the Notch3 interaction domain. Altogether, these results strongly 
suggest the recruitment of LTBP-1 into Notch3-ECD deposits by a co-aggregation 
mechanism requiring a direct interaction. 
These observations support and extend the previous results on the gain-of-toxic-function 
hypothesis by Monet-Lepretre and co-workers involving the recruitment of matricellular 
proteins into Notch3-ECD deposits. For TIMP3, they were able to demonstrate a clear 
increase in its protease activity providing first hints for a disease-related role. This 
matricellular protein is an inhibitor of ECM-degrading metalloproteases and TIMP3 
activity alterations were suggested to contribute to the impaired ECM homeostasis and 
fibrosis in small vessels in CADASIL patients (Monet-Lepretre et al., 2013). Here, LTBP-1 is 
demonstrated as a novel Notch3-ECD aggregate constituent (Figure 32). Together with the 
present data, this suggests that while structural components of the ECM such as fibrillin-1, 
fibronectin and collagens rather ubiquitously accumulate within CADASIL-affected 
vessels, direct Notch3-ECD interactors such as the matricellular proteins TIMP3 and 
LTBP-1 can be specifically trapped in Notch3-ECD aggregates. Likely, the sequestration of 
additional proteins into Notch3-ECD deposits triggers a snowball effect continuously 
promoting the recruitment of more proteins, generating new interaction surfaces and 
increasing their toxic potential. 
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Figure 32: Potential pathomechanism in CADASIL. Notch3-ECD deposits (grey bars) recruit 
LTBP-1 (green hemicycle) into deposits by a co-aggregation mechanism requiring a direct 
interaction. LTBP-1 mediates the co-sequestration of covalently bound LAP (orange dimer) into the 
deposits. Possibly, a conformational change of LAP could release mature TGF-β (blue dimer), which 
could induce the induction of ECM production.  
 
4.4 Is the TGF-β pathway dysregulated in CADASIL? 
LTBP-1 controls the extracellular storage of TGF-β by covalent association with its 
pro-domain LAP. Thus, LTBP-1 recruitment into Notch3-ECD deposits might have an 
impact on TGF-β activity. The essential step in the TGF-β signaling cascade is the release of 
the mature ligand from its association with LAP by protease-dependent or -independent 
mechanisms prior to the activation of its transmembrane receptors and the subsequent 
intracellular signaling cascade (Robertson and Rifkin, 2013). Therefore, the expression 
pattern of LAP was studied and increased levels in the tunica media of CADASIL-affected 
vessels were detected. This finding strongly suggests LTBP-1-mediated sequestration of 
LAP into Notch3-ECD deposits and indicates an involvement of the TGF-β pathway in 
CADASIL pathogenesis. 
It remains to be established whether this results in an alteration of TGF-β bioavailability 
and if so, in which way. TGF-β signaling influences a number of physiological processes 
including proliferation, differentiation, migration and apoptosis and is also a crucial 
mediator of fibrotic processes (Ruiz-Ortega et al., 2007). On vascular cells, the TGF-β has a 
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wide range of diverse effects and its function is cell-dependent. VSMCs are 
dose-dependently influenced by TGF-β: At low concentrations their migration and 
proliferation is induced by increased contractile protein expression (Rudijanto, 2007). 
Contractile vSMCs counteract daily fluctuations in arterial blood pressure to avoid 
potentially deleterious increases or decreases in cerebral blood flow. To maintain a roughly 
stable cerebral perfusion, vSMCs mediate dilation and constriction of cerebral arteries 
when blood pressure decreases and increases, respectively (Iadecola and Davisson, 2008). 
High TGF-β levels, however, inhibit the expression of contractile proteins in vSMCs 
causing cytostasis and the so-called non-contractile or synthetic phenotype (Rudijanto, 
2007). Thus, synthetic vSMCs loose their ability to contract and relax in response to blood 
pressure changes in the brain. Interestingly, the CADASIL mouse model TgNotch3R169C 
displays reduced functional reactivity of vSMCs (Joutel et al., 2010). Assumingly, elevated 
TGF-β levels in CADASIL-affected arterioles could induce the synthetic phenotype of 
vSMCs impairing their functionality and contributing to the reduced myogenic responses. 
In addition, elevated TGF-β also elicits pro-fibrotic effects on vSMCs by stimulating the 
production of ECM proteins and suppressing proteases, which degrade ECM (Massague, 
1990). The cytokine connective tissue growth factor (CTGF), secreted by endothelial cells 
and fibroblasts, is a prominent TGF-β target gene promoting fibroblast proliferation and 
matrix production of fibronectin, proteoglycans and various types of collagens (Leask and 
Abraham, 2004). Additionally, TGF-β also promotes the increased incorporation of 
fibrillin-1 into the ECM without stimulating its transcription (Kissin et al., 2002). 
Consequently, the accumulation of fibronectin, fibrillin-1 and collagens (type I, III and VI) 
(Miao et al., 2004, Miao et al., 2006, Oide et al., 2008, Dong et al., 2012) contributing to the 
prominent fibrotic thickening of CADASIL vessels could be attributed to increased TGF-β 
bioavailability.  
Dysregulated TGF-β signaling has been demonstrated in a variety of inherited vascular 
diseases including Marfan syndrome, a systemic connective tissue disorder (Doyle et al., 
2012). The disease is caused by autosomal dominant mutations in fibrillin-1 leading to 
defective microfibril formation, vessel fibrosis and vascular defects such as aortic 
aneurysms (Judge and Dietz, 2005). It is now established that increased TGF-β 
bioavailability and signaling activity is responsible for the deleterious fibrotic responses 
(Neptune et al., 2003) possibly due to ineffective incorporation of LTBP-1 into altered 
microfibrils of the vascular ECM (Gomez et al., 2009). Notch3-ECD aggregates might have 
a similar effect by sequestering LTBP-1 and preventing its incorporation into ECM. Thus, 
CADASIL and Marfan Syndrome might share a similar mechanism contributing to 
individual pathomechanisms in differently affected tissues. In Marfan syndrome, mainly 
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larger vessels such as the aorta are affected while the brain vasculature is not involved 
(Judge and Dietz, 2005).  
However, alterations in TGF-β signaling have also been reported in the cerebral 
microvasculature (Hara et al., 2009, Shiga et al., 2011). Cerebral autosomal recessive 
arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is a rare 
recessively inherited form of SVD sharing the main clinical manifestation with CADASIL, 
although additional symptoms such as alopecia (premature baldness) and vertebral disc 
herniation are also observed (Fukutake, 2011). Disease-causing recessive mutations in the 
gene encoding high temperature requirement protein A1 (HtrA1), a conserved serine 
protease, invariably result in a loss of HtrA1 activity. Consequently, a lack of substrate 
processing is considered the underlying pathomechanism (Hara et al., 2009). Studies in our 
group have shown that HtrA1 cleaves LTBP-1 in its N-terminal hinge region reducing 
LTBP-1’s ability to bind fibronectin and resulting in dysregulated TGF-β signaling 
(Beaufort et al., PNAS in press). 
Remarkably, HtrA1 was also identified in the proteomic analysis of Notch3-ECD enriched 
murine and human brain fractions (Monet-Lepretre et al., 2013). Moreover, further proteins 
with a role in TGF-β biology were found to be increased in diseased vessels. These 
included Emilin, an inhibitor of proteolytic conversion of pro-TGF-β into LAP and mature 
ligand (Hynes, 2009) and Nidogen, βig-h3/TGFBI (transforming growth factor, β induced) 
and Perlecan, all of which are TGF-β inducible ECM components (Iozzo, 1998, Melrose et 
al., 2008, Zakin and De Robertis, 2010, Monet-Lepretre et al., 2013). This lends further 
support to the hypothesis that the TGF-β pathway plays a role in CADASIL disease 
development. Surprisingly, LTBP-1 was not amongst the identified factors, which could be 
due to the use of whole brain tissue instead of isolated vessels possibly containing only 
minute amounts of LTBP-1. Alternatively, it might be difficult to detect LTBPs using mass 
spectrometry, a possibility supported by the low number of specific peptides assigned to 
LTBP-2 and LTBP-4 (Monet-Lepretre et al., 2013). 
It is tempting to speculate that a dysregulation of TGF-β activity might represent a 
common feature of both CADASIL and CARASIL. Thompson and Hakim postulated 
already in 2009 that increased TGF-β signaling might be responsible for fibrotic vessel 
alterations in sporadic SVD patients (Thompson and Hakim, 2009). Thus, a more detailed 
analysis of the different aspects of the TGF-β pathway in both diseases are required to 
substantiate its role in SVD pathogenesis. This should include a comprehensive 
examination of TGF-β signaling in TgNotch3R169C mice, which represent an established 
CADASIL model (Joutel et al., 2010). Since Notch3-ECD accumulation has been shown to 
represent one of the earliest pathological events in this model, studying its effects on TGF-β 
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pathway could deepen our understanding of disease pathomechanisms and help in 
addressing the question whether LTBP-1 co-aggregation occurs prior to vessel fibrosis. 
Additional insights might be gained by mating this strain with LTBP-1 knockout animals 
(Drews et al., 2008). 
Treatment options aiming at the restoration of normal TGF-β activity levels have already 
been proposed in Marfan syndrome. The blood pressure lowering agent losartan, which 
blocks the angiotensin II type 1 receptor and antagonizes TGF-β signaling, can prevent and 
even reverse symptoms, especially the aortic wall thickness, in a Marfan syndrome mouse 
model (Habashi et al., 2006). TGF-β acts downstream of angiotensin II, which is a potent 
vasoconstrictor inducing TGF-β1 mRNA and protein expression and subsequently vascular 
fibrosis (Ruiz-Ortega et al., 2007). In case of an increase in bioactive TGF-β in CADASIL, 
losartan might potentially have a beneficial effect on CADASIL patients as well.  
4.5 Conclusion 
Complex pathophysiological processes altering vessel morphology in CADASIL likely 
involve several interacting pathways. Recent evidence implicated a role of the TGF-β 
pathway in sporadic and familial SVD (Thompson and Hakim, 2009, Hara et al., 2009, 
Monet-Lepretre et al., 2013) and the role of TGF-β regulators fibronectin, fibrillin-1 and 
members of the LTBP family in CADASIL-related Notch3-ECD aggregation was 
investigated. LTBP-1 was identified as a Notch3-ECD interacting protein, which 
co-aggregates into CADASIL-specific deposits. Likely, LTBP-1 mediates the recruitment of 
its covalent interaction partner LAP with the possible consequence of uncontrolled release 
of mature TGF-β from its extracellular storage (see Figure 32). This could evoke fibrotic 
processes such as excess deposition of collagens, fibrillin-1 and fibronectin. Especially in 
small arterioles, the massively increased vessel wall thickness is responsible for the 
narrowing of the vascular lumen. Vessel wall modifications promote decreased cerebral 
blood flow, reduced vasoreactivity and chronic subcortical ischemia all of which are critical 
for the development of stroke and vascular dementia (Brulin et al., 2002, Miao et al., 2004).  
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